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Abstract  
In vitro expanded neural stem cells provide an important cellular model to explore 
mechanisms of neural development, for modelling of disease, and in the longer term may 
have applications in new types of stem cell-based therapies. However, our ability to steer 
neural stem (NS) cell lines into specific desired lineages in vitro remains limited. PDGFRα is 
one of the earliest markers of the transition of neural stem cells to oligodendrocyte 
progenitors. I established and characterised a novel set of mouse NS cell lines that report the 
activation of PDGFRα via expression of an H2B:GFP ‘knock-in’. Three clonal ‘PG1’ cell 
lines were fully characterised. Under self-renewing conditions I found <1% of NS cell 
express the H2B:GFP reporter but this increases to ~15-20% following induction of 
differentiation. Using this cellular model system I carried out a high-content chemical screen 
of a diverse collection of 463 pharmacologically active small molecule modulators of ‘stem 
cell pathways’ and kinase inhibitors, to identify those capable of modulating NS cell self-
renewal and differentiation.  I did not uncover any small molecules capable of promoting 
OPC lineage specification. However, I found multiple HDAC inhibitors that were highly 
effective in blocking the activation of PDGFRα, a finding that mirrors published studies 
implicating HDAC inhibition in the later differentiation of OPCs to oligodendrocytes. Three 
further compounds, Nigericin (an ionophore), Withaferin (a steroidal lactone) and NFkB 
inhibitor also completely blocked OPC commitment. I focused on the specific cellular 
responses and downstream molecular events triggered by these molecules and tested their 
differentiation potential on human NS cells and malignant glioblastoma-derived NS cells.  
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Chapter 1 Introduction 
1.1 Development of the central nervous system 
The formation of the nervous system is one of the most fascinating subjects of biology.  The 
central nervous system (CNS) in vertebrates consists of the brain and the spinal cord. There 
are three major classes of cell types in the CNS: neurons, oligodendrocytes and astrocytes.  
The latter two are termed glial cells. Glial cells provide a physical support and protection for 
neurons. Oligodendrocytes insulate axons with a myelin sheath, which enhances saltatory 
conduction through the nodes of Ranvier. Astrocytes maintain extracellular ion balance and 
provide nutrients to neurons and are also an integral component of the blood-brain barrier 
protection, where they support endothelial cells biochemically through their projections 
called glial limitans.  
There are known to be many hundreds, or even thousands, of different neuronal subtypes and 
it is increasingly clear that many distinct subtypes of glia exist. Most research effort has been 
devoted to understanding the generation and function of neurons, with glia receiving less 
attention. However, the total number of glial cells in CNS is at around 10-fold higher than 
neurons (Rowitch 2004). Macrophages, termed microglia, form the immune defence of the 
brain. They are usually not mentioned in the classical classification of CNS cells as they are 
formed in the bone marrow and then migrate to the brain as myeloid progenitor cells (Ritter, 
Banin et al. 2006).  
The nervous system arises from the outermost tissue layer of the embryo, called the 
ectoderm, in a process called neural induction (Figure 1A). The ectoderm becomes specified 
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to give rise to epidermis and the neural plate, which requires formation of neuroectoderm 
induced by signalling from the mesoderm. At the onset of gastrulation mesodermal cells form 
a layer in between the endoderm and the ectoderm and go on to form a structure called the 
notochord. Notochord signalling to adjacent tissues leads the overlying ectodermal cells to 
acquire neuroectodermal character, with the remainder of the ectoderm giving rise to the 
epidermis.  
During human development, the neuroectoderm is formed in the third week of development 
and it is responsible for the creation of the neural plate along the dorsal side of the embryo. In 
the fourth week of development a groove is formed in the neural plate allowing it to wrap in 
on itself to a make a hollow neural tube in the process called neurulation. Some cells stop 
dividing and differentiate into neurons and glial cells, the main cellular components of the 
brain. Proper development of the neural tube is crucial as it gives rise to the brain and spinal 
cord and it is a source of majority of neurons and glial cells in the mature human. Neurons 
are born at the earliest stages of CNS development and migrate to different parts of the 
developing brain, where they self-organise into different brain structures. The glial cells 
emerge at later embryonic time-points and postnatally. 
1.2 Regulation of cell differentiation in the CNS 
The nervous system is formed from an undifferentiated layer of embryonic neuroectodermal 
progenitor cells. The blockade of signalling of the bone morphogenetic proteins (BMPs) 
during gastrulation is sufficient to induce the neuralisation of the ectoderm in Xenopus 
embryos. Two antagonists of BMP activity include Noggin and Chordin, which are released 
by the organiser (node in mammals). Complex patterning of these neuroectodermal 
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progenitors occurs via different concentrations of signalling molecules (morphogens), such as 
Sonic hedgehog (Shh). Early embryological experiments identified somites and notochord to 
be responsible for the dorsoventral (DV) patterning. Shh is produced by the floor plate. It 
induces ventral neural cell types in a concentration-dependent manner. BMPs are produced 
by the roof plate. They are responsible for inducing dorsal neural cell types in a 
concentration-dependent manner. Retinoic acid is then used for motor neuron differentiation 
and to define motor neuron subtypes (Figure 1B) (Wilson and Maden 2005). 
The acquisition of a specific neural cell fate depends on the initial spatial coordinates of a 
precursor cell within the neural plate, because of the environment created by signalling 
molecules, which progressively restrict the developmental potential. The spinal cord, which is 
structurally simpler than the brain, has provided the best studied example for defining 
mechanisms controlling the patterning along the dorsal-ventral (DV) axis. The spinal cord is 
divided into 11 domains of neural progenitors: 5 ventral domains called p3, pMN, p2, p1 and 
p1 (from ventral to dorsal) and 6 dorsal domains called dP1, dP2, dP3, dP4, dP5 and dP6 
(from dorsal to ventral). These domains express characteristic transcription factors, which 
determine the type of neuronal cell type created. The competing patterning signals are 
secreted from the ventral floor plate and the dorsal roof plate. Sonic hedgehog composes the 
ventral floor plate signalling, opposed by members of the Wingless-type MMTV integration 
site (Wnt) and BMP families from the roof plate. Non-BMP members of the transforming 
growth factor-beta (TGF-beta) superfamily are also involved in this process.  
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Figure 1. Key elements of the central nervous system development. (A) Schematic representing steps leading to 
the development of a brain; (B) Schematic showing key factors regulating the patterning of the nervous system;  
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The rostral caudal patterning involves fibroblast growth factors (FGFs) and retinoic acid 
mediated signalling. FGFs are produced by the caudal mesoderm, and must be down-
regulated before the neural differentiation process can occur. FGF-8 downregulation is 
important for neuronal differentiation.  Retinoic acid is a somatic signal, which opposes  
FGF-8 activity in neuroepithelium and paraxial mesoderm, where it controls somite boundary 
position. Retinoic acid is then further required for the expression of key ventral neural 
patterning genes (Diez del Corral, Olivera-Martinez et al. 2003, Novitch, Wichterle et al. 
2003).  
In the spinal cord, oligodendrocytes are firstly generated ventrally in the pMN domain and 
then later in the more ventral dP3-dP5 domains. The pMN domain initially gives rise to 
motoneurons and then to the majority of spinal cord OPCs. The identity of the pMN domain 
depends on the Shh gradient along the dorsoventral axis of the spinal cord, which results in 
the concentration-dependent induction of different transcription factors. Nkx2.2 is expressed 
only under the highest concentration of Shh in the most ventral region of the domain. On the 
other hand, Irx3 requires lower concentrations of Shh. Other closely related transcription 
factors like Nkx6.1 and Nkx6.2 can be induced under a wider range of Shh concentration, 
which allows them to be coexpressed with Nkx2.2 and Irx3 in their respective domains, but 
also in the domain between them. Expression of Olig2 gene is repressed by Nkx2.2 and Irx3, 
but it is a target gene for Nkx6.1 and Nkx6.2, thus it is expressed only between Nkx2.2 and 
Irx3 domains, which corresponds to the pMN domain. Therefore Olig2 is considered to be a 
marker for the pMN domain and its pluripotent neuroepithelial precursor cells. It is required 
for the formation of both oligodendrocytes and motoneurons (Kettenmann and Ransom 
2013).  
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1.3 Neural stem cells 
1.3.1 History of neural stem cell research 
Neural stem cells are defined as multipotent, self-renewing cells, which can differentiate into 
neurons and glia (Figure 2). Such cells exist transiently during foetal development (and are 
termed radial glia), but in the 1990’s it was also confirmed that they exist in the adult 
mammalian brain where they exist for the life-time of the animal. Adult neurogenesis was 
first observed in the 1960’s following rat brain studies, where brain lesions were created, 
followed by an injection of thymidine-H(3); traumatized areas were characterized by 
labelling of glial cells, but also some neurons and neuroblasts, suggesting the proliferation of 
neurons in adult rats (Altman 1962). This led to further studies in the 1990’s, which identified 
neural stem cells, within the ventricular zone of the lateral wall of the forebrain ventricle, as 
well as the hippocampus (Eriksson, Perfilieva et al. 1998). These cells contribute to tissue 
homeostasis and the production of new neurons in the adult central nervous system, within 
both the olfactory bulbs and hippocampus (Reynolds and Weiss 1992, Morshead, Reynolds et 
al. 1994). Adult neural stem cells were shown to be derived from foetal radial glia (Merkle, 
Tramontin et al. 2004).  
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Figure 2. Neural stem cells can differentiate into mature neural cell types: neurons and glia, inclusive of 
astrocytes and oligodendrocytes. Images show neural cell types and their characteristic markers, TUBB3 for 
neurons, GFAP for astrocytes and O4 for oligodendrocytes; Image courtesy of Dr Steven Pollard, University of 
Edinburgh, UK;  
1.3.2 Neural stem cell niche 
Factors such as cell-cell interactions, vasculature, basal lamina and the extracellular matrix 
define a specific neural stem cell niche which has common features in both the SVZ and 
subgranular zone (SGZ) of the hippocampus (Doetsch 2003, Riquelme, Drapeau et al. 2008).  
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Adult SVZ NSCs have been shown to exist within a neurovascular niche consisting of two 
specific sub-localized compartments: the basal vasculature niche is a rich network of blood 
vessels and the apical ependymal niche lines the ventricles and is composed of stem cells 
intercalated with ciliated ependymal cells (Pastrana, Cheng et al. 2009). Alvarez-Buylla and 
Lim summarised the shared hallmarks of the neural stem cell niche as follows: (1) astrocytes 
serve as both stem cell and niche cell, (2) a basal lamina and concomitant vasculogenesis may 
be essential components of the niche, and (3) “embryonic” molecular morphogens and 
signals persist in these niches and play critical roles for adult neurogenesis. They termed 
these niches as “displaced” neuroepithelium, where cells and local signals preserve 
embryonic character to maintain neurogenesis for life (Alvarez-Buylla and Lim 2004). 
Adult SVZ niche can be described in terms of three types of cells, called type A, -B, and –C 
cells (Figure 3). Type B cell have astrocytic features and are considered to be stem cells, 
which form migrating neuroblasts, also known as type A. These cells, via a rapidly dividing 
transit amplifying cell (type C) migrate rostrally to the olfactory bulb. Unlike type A cell, the 
type C divide rapidly, but remain stationary. Type B cells divide slowly and ensheath type A 
cells with cellular processes. Ependymal cells line wall of the lateral ventricle. 
Intraventricular infusion of pigment epithelium-derived factor (PEDF) activates slowly 
dividing stem cells in the murine SVZ, while its blockade has an opposite effect, reducing 
their cycling. PEDF is secreted by components of the SVZ niche (Ramirez-Castillejo, 
Sanchez-Sanchez et al. 2006).  Neural stem cells are stimulated by soluble factors released by 
endothelial cells, which stimulate self-renewal by activating Notch and Hes1, as endothelial 
coculture stimulates neuroepithelial cell contact (Shen, Goderie et al. 2004). Infusion of EGF 
into the lateral ventricle causes progenitor cells to proliferate and migrate towards the 
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ventricle. Fricker-Gates et al. transplanted in vitro expanded immature progenitor cells into 
the striatum of adult rats followed by a continuous infusion of EGF into the lateral ventricle 
and observed that the transplanted cells migrated towards the ventricle and proliferated, 
which was confirmed as cells incorporated bromodeoxyuridine (BrdU) (Fricker-Gates, 
Winkler et al. 2000). Kuhn et al. observed that both EGF and FGF-2 can expand the SVZ 
population of progenitor cells, but only FGF-2 was able to increase the number of newly born 
neurons in the olfactory bulb. EGF had an opposite effect, decreasing the amount of newborn 
neurons and instead increasing the generation of astrocytes in the olfactory bulb. Infusion of 
either of the growth factors did not affect the proliferation of the hippocampal progenitors 
(Kuhn, Winkler et al. 1997). Infusion of PDGF alone was also shown to have proliferative 
potential.  PDGF arrests the formation of neuroblasts and induces proliferation of SVZ B 
cells, contributing to formation of large hyperplasias, which had some characteristics of 
gliomas (Jackson, Garcia-Verdugo et al. 2006).  
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Figure 3. Cell types of the adult SVZ niche.   (A) Schematic representing relationship between the key three cell 
types of the SVZ niche. Type B cells give rise to type A cells via a transit amplifying cell, called type C; (B) 
Schematic of frontal section of the adult mouse brain showing the subventricular zone adjacent to the lateral 
ventricle (LV). SVZ niche astrocytes in this region (B, yellow) are considered to be stem cells which can 
generate migrating neuroblasts (A, green). These cells are destined for the olfactory bulb via a transit-amplifying 
cell (C, blue). Ependymal cells (E, grey) line the walls of the lateral ventricle. 
1.3.3 Molecular hallmarks and signalling pathways regulating neural stem cells 
There has been a great deal of attention focussed on the identification of markers that can 
identify and enable prospective isolation of foetal and adult neural stem cells. One of the first 
markers to be identified was reported by Lendahl et al., who identified Nestin, a class VI 
intermediate filament protein, to be a molecule whose expression distinguishes stem cells 
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from the more differentiated cells in the neural tube (Lendahl, Zimmerman et al. 1990, 
Doetsch, Caille et al. 1999). The presence of Nestin was observed in adult neural stem cells, 
both in vitro and in vivo (Reynolds and Weiss 1992, Morshead, Reynolds et al. 1994). 
One of the best markers, and known regulators of neural stem cell identity is Sox2. Sox2 is 
expressed by neural stem cells at embryonic and adult stage (Ellis, Fagan et al. 2004). It is 
required to maintain their proliferative ability by in part regulating Shh. In a study by Favaro 
et al. they showed that a deletion of Sox2 causes a loss in hippocampal neurogenesis, which 
was similar to the already observed loss due to Shh deletion. Chromatin precipitation 
identified Shh as a Sox2 target. They concluded that neural stem cells control their status 
through Sox2-dependent autocrine mechanisms (Favaro, Valotta et al. 2009).  Mouse 
embryonic studies presented cerebral malformations, parenchymal loss and ventricle 
enlargement when Sox2 was deleted. Abnormalities in neurons, degeneration and 
cytoplasmic protein aggregates were observed at the cellular level (Ferri, Cavallaro et al. 
2004).  
Other frequently used markers include GFAP (only quiescent cells), Nestin, Musashi 1 and 
Musashi 2 with CD133 being the most controversial. CD133 was widely used as a marker of 
neural stem cell identity with some studies showing that it is possible to expand cell lines, 
which are originally negative for this marker (Sun, Kong et al. 2009, Chen, Guo et al. 2012).  
Adult neural stem cells maintain a glial identity similar to embryonic radial glia (Doetsch 
2003). It was suggested that two subpopulations of active and quiescent neural stem cells are 
maintained in the adult organism, with both having their cooperative function (Li and Clevers 
2010). Recent attention has focussed on determining the phenotypic differences between 
active proliferating neural stem cells and those quiescent neural stem cells. CD133 may mark 
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a quiescent neural stem cell state (Beckervordersandforth, Tripathi et al. 2010). More recent 
studies have defined a key role for TLX (Qu, Sun et al. 2010) and NFI families (Martynoga, 
Mateo et al. 2013). 
Extrinsic signals that control neural stem cell self-renewal and proliferation are numerous. 
BMP and Wnt signalling regulate function of adult neural stem cells throughout an 
individual’s lifetime (Wexler, Paucer et al. 2009, Mira, Andreu et al. 2010), with Wnt/beta-
catenin signalling involved in the proliferation of progenitor cells in the SVZ of the adult 
mouse brain (Hirabayashi, Itoh et al. 2004, Adachi, Mirzadeh et al. 2007). BMP on the other 
hand promotes cell cycle exit and causes differentiation of neural progenitors (Gross, Mehler 
et al. 1996), and likely in combination with FGF signalling is involved in sustaining the 
quiescent neural stem cell state (Mira, Andreu et al. 2010, Martynoga, Mateo et al. 2013) .  
Other known extrinsic regulators include Notch and EGFR pathways (Alexson, Hitoshi et al. 
2006, Aguirre, Rubio et al. 2010). Notch is responsible for regulation of identity and self-
renewal of neural stem cells, while EGFR controls proliferation and migration of transiently 
amplifying progenitors and likely marks the transition from quiescent to ‘active’ proliferative 
neural stem cells (Pastrana, Cheng et al. 2009). Pigment epithelium-derived factor (PEDF), 
CXCL12 and FGF-2 are also involved in the self-maintenance of neural stem cells through 
non-cell-autonomous effects (Ramirez-Castillejo, Sanchez-Sanchez et al. 2006, Kokovay, 
Goderie et al. 2010). 
Notch signalling plays role in regulating cell-to-cell communication, proliferation and 
differentiation, and apoptosis (Artavanis-Tsakonas, Rand et al. 1999).  It regulates numbers 
and promotes survival of neural stem cells through induction of Hes3 and Shh through 
activation of cytoplasmic signals, including serine/threonine kinase Akt, STAT3 and mTOR. 
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When administered into brains of adult rats an increase in newly generated precursor cells 
can be observed after ischemic injury. Notch signalling is opposed by a control mechanism 
involving p38 mitogen-activated protein kinase (Androutsellis-Theotokis, Leker et al. 2006).  
1.4 In vitro culture of neural stem cells 
Large-scale sources of neural stem cells play an important role in basic research and have a 
potential to be used in novel treatments for neurological disorders. Oncogene-immortalised 
stem cells, neurospheres, and embryonic stem cell (ES)-derived neural stem cells have been 
widely used in vitro as sources of neural stem cells (Gottlieb 2002) – although how closely 
these relate to in vivo neural stem cells is unresolved (Pastrana, Silva-Vargas et al. 2011).  
The neurosphere assay has been widely used to study neural stem cells in vitro. It is based on 
the ability of neural stem cells to self-renew in the presence of EGF and FGF-2 when cultured 
in vitro (Vescovi, Parati et al. 1999, Azari, Rahman et al. 2010). In this assay cells are grown 
in suspension, as floating cell clusters, termed neurospheres. One of the caveats of this 
method is the fact that the clusters are composed of stem, progenitor and differentiating cells, 
and often a large proportion of dying cells. Another caveat is the possibility of sphere 
formation by transient-amplifying progenitor cells (Reynolds and Rietze 2005, Marshall, 
Reynolds et al. 2007, Ahmed 2009). Neurospheres formed by the SVZ cells cultured in vitro 
in the presence of EGF were shown to be derived from highly mitotic, Dlx2-positive, transit-
amplifying C cells and not from the quiescent stem cells in vivo (Doetsch, Petreanu et al. 
2002).  EGF causes C cells to downregulate Dlx2 and arrest neuronal production, making 
these cells highly proliferative and invasive. A neural colony forming cell assay was designed 
to discriminate between the bona fide neural stem cells and neural progenitor cells 
(Deleyrolle and Reynolds 2009, Azari, Rahman et al. 2010). In this collagen based semi-solid 
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assay, it is possible to discriminate stem from progenitor cells, because of their long-term 
proliferative potential.  
Neural stem cells can be also grown as adherent NS cell lines, which show a multi-lineage 
differentiation ability and self-renewal potential (Conti, Pollard et al. 2005, Pollard, Conti et 
al. 2006, Pollard 2013). The term ‘NS cells’ was used to highlight the similar experimental 
attributes compared with ES cells. Initially, the NS cell lines were derived from the ES cells 
differentiated into heterogeneous neuroepithelial progenitors cultured as an adherent 
monolayer. After a number of passages cells lost the heterogeneous morphology and 
uniformly expressed Sox2 and Nestin. The process was facilitated by FGF-2 and EGF present 
in a defined basal media (Ying, Stavridis et al. 2003). 
Adherent culture conditions offer a number of advantages over the neurosphere assay and 
other methods. NS cell line propagation in vitro reduces the need for a constant supply of 
embryos. All cells in the layer are equally exposed to EGF and FGF-2. This allows for a 
suppression of differentiation and apoptosis, which can occur in the neurosphere assay, 
enabling propagation of homogenous populations. NS cell lines have proven useful in 
defining transcriptional targets of key transcriptional regulators: Mash1 (Gohlke, Armant et 
al. 2008) and REST (Johnson, Teh et al. 2008), and were also exploited in studies of 
reprogramming (Stricker, Feber et al. 2013, Stricker and Pollard 2014). NS cell lines can be 
easily expanded, which makes them suitable for a number of applications including genome 
manipulations, gene expression profiling and biochemical analysis. Moreover, the adherent 
culture is well suited for chemical screening, because it is possible to monitor and track 
individual cells (Pollard, Clarke et al. 2009). Clonal cell lines can easily be generated and 
‘picked’ – avoiding the need for elaborate semi-solid suspension culture regimes. 
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Similarly to neurosphere culture, adherent NS cell lines also have limitations. Cells grown 
this way display changes in dorsal-ventral positional identity, which can limit their 
differentiation potential to specific type of neurons or glial cells (Conti and Cattaneo 2010) – 
although anterior-posterior markers such as Hox gene expression seems to be preserved (Sun, 
Pollard et al. 2008). The sustained exposure to FGF-2 results in upregulation of ventral 
markers such as Olig2 and Mash1, which in turn limit neuronal differentiation potential to 
GABAergic interneurons (Gabay, Lowell et al. 2003). Culture conditions could also affect 
temporal identity of NS cells as FGF-2 induces expression of EGFR, which is usually found 
in later foetal stages (Pollard, Wallbank et al. 2008).  Thus, in vitro propagated neural stem 
cells share features with late foetal gliogenic progenitors and radial glia, and most likely do 
not have potential to generate all neuronal and glial cell types of the nervous system. 
Adherent culture of neural stem cells is particularly well suited to high content drug 
screening, where the ability to identify and track individual cells using automated software is 
crucial (see Chapter 4).  
1.5 Oligodendrocyte differentiation 
Much progress is made in our understanding of the origins of the oligodendrocytes during 
development, and identification of some key regulatory genes and useful markers 
(Richardson, Kessaris et al. 2006). In the early developing nervous system gradients of 
activity of Shh and BMP are responsible for the initial induction of lineage-specific 
transcription factors that specify the oligodendrocyte lineage (e.g. Olig2 and Nkx2.2).  
Oligodendrocyte progenitor cells (OPCs) initially emerge from the ventral neural tube 
(Rowitch 2004).  The critical downstream transcriptional regulators that are required for 
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promoting the oligodendrocyte differentiation program include Olig2, Nkx2.2, and Sox10.  
Sox10 is also crucial for glial development in the peripheral nervous system and is restricted 
to myelin-forming oligodendroglial cells of the central nervous system, providing a useful 
marker and functionally important regulator of oligodendrocyte differentiation (Stolt, 
Rehberg et al. 2002). Dephosphorylation of Olig2 at serine 147 triggers the switch from 
motor neuron production to oligodendrocyte precursors in the embryonic spinal cord (Li, de 
Faria et al. 2011). Transcription factors Nkx2.2 and Nkx6.2 are co-expressed in myelinating 
oligodendrocytes suggesting their involvement in maintenance and creation of the myelin 
sheath (Cai, Zhu et al. 2010). 
Oligodendrocytes develop postnatally from PDGFRα-positive OPCs that emerge during 
foetal development in the pMN domain. OPCs depend on PDGF-A binding to PDGFRα for 
continued proliferation and migration. PDGF-A controls the number of OPCs both in embryo 
and in adult brain (van Heyningen, Calver et al. 2001, Woodruff, Fruttiger et al. 2004). 
PDGF-A deficient mice, which survive postnatally suffer from severe hypomyelination 
(Calver, Hall et al. 1998, Fruttiger, Karlsson et al. 1999). SVZ cells stimulated with PDGF-A 
differentiate towards PDGFRα-positive cells leading towards oligodendroglial differentiation 
(Jackson, Garcia-Verdugo et al. 2006, Menn, Garcia-Verdugo et al. 2006).  
PDGF-A induces embryonic Nestin-positive neural progenitor cells to become NG2-positive 
oligodendrocyte progenitor cells (Hu, Fu et al. 2008). PDGF and PDGFR is also known to be 
involved in many other developmental processes, from lung alveolar myofibroblast 
development and alveogenesis (Bostrom, Willetts et al. 1996) to cardiovascular and renal 
development (Leveen, Pekny et al. 1994, Soriano 1994). In particular, PDGFRα is required 
for the development of the neural crest and for patterning of the somites (Soriano 1997). 
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Full differentiation of OPCs into oligodendrocytes occurs between postnatal days 4-12 (P4-
P12). Mature markers include 2′,3′-cyclic nucleotide 3’-phosphohydrolase (CNPase), myelin 
basic protein (MBP), proteolipid protein (PLP) and myelin-associated glycoprotein (MAG) 
(Patel, McCandless et al. 2010) (Figure 4). 
In vitro studies of rat oligodendrocyte progenitors through the 1980s and 1990s led to the 
description of two types of astrocytes called type 1 and type 2 astrocytes. Type 1 astrocytes 
were defined as cells with fibroblast-like morphology, the ability to proliferate in the 
presence of EGF and were A2B5-negative. Type 2 astrocytes divided infrequently in culture 
and bound tetanus toxin and A2B5 antibody (Raff, Miller et al. 1983). Studies performed on 
rat optic nerve identified cells with an ability to differentiate into type 2 astrocytes if cultured 
Figure 4. Markers of oligodendrocyte differentiation.   Adapted from (Zhang 2001). Differentiation of 
oligodendrocytes is a stepwise process from bipolar progenitors to pre-oligodendrocytes with multiple 
processes, followed by membrane-sheath-bearing oligodendrocytes and myelinating oligodendrocytes. 
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in the presence of fetal calf serum, and into oligodendrocytes in its absence, suggesting the 
A2B5-positive cells as progenitors for both oligodendrocyte and type 2 astrocyte lineages 
(the ‘O2-A’ progenitors) (Raff, Miller et al. 1983). How the O2-A progenitor relates to the 
radial glia and other progenitors within the developing mouse CNS remains unclear (Rowitch 
and Kriegstein 2010).  
In vitro differentiation of OPCs into functional oligodendrocytes can be triggered by a 
withdrawal of PDGF-AA and an addition of T3, thyroid hormone (Barres, Lazar et al. 1994, 
Ahlgren, Wallace et al. 1997, Baas, Bourbeau et al. 1997). While NS cell lines, from both 
mouse and human, generate mature oligodendrocytes using similar protocols, this is highly 
inefficient (1-10%). Improved understanding of the molecular mechanisms controlling NS 
cell lineage choice in vitro may elucidate principles of cell differentiation control in vivo. NS 
cell conversion to oligodendrocytes in vitro is likely to mirror the transition from NS cell 
through oligodendrocyte progenitor cell (OPC) to a mature oligodendrocyte in vivo. Efficient 
production of human oligodendrocytes in the laboratory may open up new opportunities for 
cell transplantation medicine, for example in the treatment of demyelinating disorders such as 
multiple sclerosis.  
1.6 Glioma and glioblastoma  
1.6.1 Background 
Glioma is a type of a brain tumour that arises most frequently in the forebrain. Gliomas make 
up 80% of all malignant brain tumour cases.  They can be characterised according to the 
histological appearance and include: ependymoma, oligodendrolioma, and most frequently 
astrocytoma. However, gliomas can be highly heterogeneous both between patients and 
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within individual tumours – where mixtures of astrocyte-like cells, oligodendrocyte and 
immature progenitors exist. An additional form of classification includes their grade, 
according to the pathologic evaluation of the extent of aggressive features. Low grade 
gliomas are well differentiated and have a better prognosis for patients. They can grow 
slowly over a period of years and can remain unidentified until symptoms arise. High grade 
gliomas are anaplastic, malignant and have a worse prognosis. They are highly vascular with 
a tendency to infiltrate, making surgical resection of the tumour impossible. They are 
characterised by extensive areas of necrosis and hypoxia.  
High grade gliomas are called glioblastoma (GBM) or high grade astrocytoma, and these 
tumours are highly malignant and typically grow back after the removal surgery.  About half 
of GBM cases are bilateral or occupy more than one lobe of a hemisphere. Prognosis is a 
dismal 14-month median survival. Symptoms of brain gliomas include headaches, nausea, 
seizures and vomiting. An increase in intracranial pressure can also lead to cranial nerve 
disorders. Cell type, grade of malignancy and location of a tumour can influence treatment 
possibilities. Standard treatment includes resection, followed by a chemo- and radiotherapy 
(Adamson, Kanu et al. 2009).  
GBM is the most common and most malignant primary brain tumour in adults (Ohgaki, 
Dessen et al. 2004, Ohgaki and Kleihues 2005, Louis, Ohgaki et al. 2007). It typically 
contains cells with neural stem cell and glial progenitor characteristics (Murat, Migliavacca et 
al. 2008). GBM is characterised by a presence of hyperplastic blood vessels and small areas 
of necrotizing tissues surrounded by anaplastic cells. Usually formed in the cerebral white 
matter, GBMs grow quickly before symptoms are observed. 
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The causes of gliomas are not completely understood, with only a minority of cases being 
hereditary genetic disorders, such as tuberous sclerosis complex and neurofibromatoses (type 
1 and 2) being a predictor of their development. Genetic mutations frequently associated with 
gliomas include mutations in tumour suppressor protein 53 (TRP53), phosphatase and tensin 
homolog (PTEN) and activating mutations in epidermal growth factor receptor (EGFR).  
A range of subtypes of GBM have been described and various other disease variants include 
fibrillary/epithelial GBM, small cell astrocytoma (SCA), GBM with oligodendroglial 
component (GBMO), GBM with primitive neuroectodermal features (GBM-PNET), 
gemistocytic astrocytoma (GA), granular cell astrocytoma (GCA), paediatric high grade 
glioma (HCG) as well as diffuse intrinsic pontine glioma (DIPG) (Karsy, Gelbman et al. 
2012). The current WHO classification system recognizes three distinct GBM variants, 
classic GBM, gliosarcoma (GS) and giant-cell GBM (GC-GBM) (Louis, Ohgaki et al. 2007). 
The giant-cell GBM is characterised by a prevalence of multinucleated (more than 20 nuclei), 
giant cells with diameter up to 400 um. Gliosarcoma is rare accounting for approximately 
2.1% of all GBMs and contains sarcomatous components, malignant cells of mesenchymal 
origin (Ayadi, Charfi et al. 2010). How these distinct diseases emerge and the molecular 
underpinnings of GBM subtypes are only now being uncovered.  
1.6.2 Genetics of human glioblastoma 
GBM can be defined as ‘primary GBM’, which presents acutely as a high grade disease with 
mutations in EGFR, PTEN and INK4A/ARF (CDKN2A) and the secondary GBM subtype 
evolving from the slow progression of low grade disease with PDGF and TP53 events 
(Kleihues and Ohgaki 1999).  The vast majority of GBMs develop rapidly after a short 
clinical history and without evidence of a less malignant precursor lesion. Over 60% of 
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patients with primary GBM have a clinical history of less than 3 months (Ohgaki, Dessen et 
al. 2004).  Secondary GBMs are more common in younger patients with mean age of 45 
versus 62 for primary GBM and account for 10% of cases (Ohgaki and Kleihues 2009). 
These tumours grow slower through a progression from low-grade diffuse astrocytoma 
(WHO grade II) or anaplastic astrocytoma (WHO grade III). The mean time of progression 
from these tumours to GBM was estimated at 5.3 years and 1.4 years respectively. The 
genomic classification of GBM includes four subtypes: classical, proneural, neural, and 
mesenchymal (Verhaak, Hoadley et al. 2010) (Figure 5). Classical subtype contains extra 
copies of EGFR gene with rarely mutated TP53 (Hayden 2010). Proneural has high rates of 
TP53, PDGFRA and IDH1 alterations. Mesenchymal subtype contains mutations in NF1, a 
gene encoding Neurofibromatosis type 1, and less alterations and lower expression levels of 
EGFR than any other subtype (Kuehn 2010).  The neural subtype expresses neuron markers, 
such as NEFL, GABRA1, SYT1 and SLC12A5 (Verhaak, Hoadley et al. 2010).   
Large scale sequencing of GBM genome led to discovery of novel signalling pathways and 
genetic alterations, which could create a new direction in GBM treatment (Cancer Genome 
Atlas Research 2008, Parsons, Jones et al. 2008). Despite being histologically 
indistinguishable, the mRNA and protein expression profiles of primary and secondary 
GBMs are significantly different (Ohgaki and Kleihues 2007).  
The malignant transformation of GBM cancer cells, as in case of other malignancies, could 
be due to multiple chromosomal aberrations, nucleotide substitutions and epigenetic 
modifications. The large-scale multi-dimensional analysis of these molecular characteristics 
in human cancer is aim of The Cancer Genome Atlas (TCGA) project.  
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Figure 5. Summary of key genomic alterations across GBM subtypes.  Adapted from (Verhaak, Hoadley et al. 
2010).  
The data from TCGA analyses of GBM samples provided new insights into the frequency of 
ERBB2, NF1 and TP53, frequent mutations of the phosphatidylinositol-3-OH kinase 
regulatory subunit gene PIK3R1 and a network view of the pathways altered in GBM 
development. Integrated analysis of mutation, DNA methylation and clinical treatment data 
revealed a correlation between O
6
-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation and a hypermutator phenotype consequent to a mismatch repair 
deficiency in treated GBMs (Cancer Genome Atlas Research 2008). MGMT removes 
promutagenic alkyl groups from O
6
-methylguanine (Pegg 2000). This molecule causes G:C -
> A:T mutations during DNA replication (Margison, Santibanez Koref et al. 2002, Kaina 
2004). A methylation-specific PCR approach showed a correlation between the MGMT 
promoter methylation status and long-term patient survival with higher methylation rate 
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associated with long-term survival GBM type (Martinez, Schackert et al. 2007). Epigenetic 
silencing of the MGMT DNA-repair gene using promoter methylation compromised DNA 
repair and was shown to be associated with longer survival in GBM patients, irrespective of 
treatment used, with patients treated with temozolomide and radiotherapy with a significantly 
longer survival (Hegi, Diserens et al. 2005, Criniere, Kaloshi et al. 2007).  
The analysis of protein-coding genes in GBMs led to identification of IDH1 mutations 
(Parsons, Jones et al. 2008). Subsequent studies identified IDH1 mutations to be more 
frequent in secondary than in primary GBMs (Balss, Meyer et al. 2008, Watanabe, Nobusawa 
et al. 2009, Yan, Parsons et al. 2009, Bleeker, Molenaar et al. 2012). This is contrasted by 
rare IDH1 mutations in primary GBMs, suggesting different cells of origin (Ohgaki and 
Kleihues 2009). IDH1 is localised on 2q33.3 (Narahara, Kimura et al. 1985). The IDH1 
protein catalyses oxidative carboxylation of isocitrate to α-ketoglutarate, which results in the 
production of NADPH in the citric acid cycle (Geisbrecht and Gould 1999). Unlike other 
IDH molecules which are present in mitochondria, the IDH1 is present in the cytosol.  
Mutations of IDH1 in GBMs cause formation of inactive heterodimers, which impair the 
enzyme’s affinity for its substrate and lead to increased levels of hypoxia-inducible factor 
subunit HIF-1α, a transcription factor which can facilitate tumour growth (Yan, Parsons et al. 
2009). IDH1 mutations are currently considered the only genetic alterations frequent among 
oligodendrogliomas, astrocytomas and oligoastrocytomas suggesting a critical role of IDH 
pathways in initial tumour formation (Watanabe, Nobusawa et al. 2009).  
Approximately 40% of primary GBMs carry EGFR amplification. This however, is very rare 
in secondary GBMs (Ekstrand, Sugawa et al. 1992, Watanabe, Tachibana et al. 1996, Ohgaki, 
Dessen et al. 2004). EGFR mutation called EGFRvIII, characterised by deletion of exons 2-7 
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is the most common EGFR variant in GBM patients. It shows a constitutive activation of the 
receptor and exerts mitogenic effects (Huang, Nagane et al. 1997). Growth factor receptors 
like EGFR and PDGFR are activated when their respective ligands bind to their extracellular 
domain. This leads to the activation of intracellular signalling cascades, one of which is PI3K 
pathway. Following membrane receptor activation, phosphatidylinositol 3-kinase (PI3K) is 
recruited to the cell membrane. Composed of a catalytically active protein p110a and a 
regulatory protein p85a, the PI3K complex phosphorylates phosphatidynositiol-4,5-
bisphosphate (PIP2) to the respective 3-phosphate (PIP3), which activates downstream 
effector molecules like AKT (protein kinase B) and mTOR. This signalling cascade results in 
cell proliferation and increased cell survival due to the blockade of apoptosis. The regulatory 
molecule, PTEN, is capable of inhibiting the PIP3 signal and inhibiting the proliferation 
process (Mellinghoff, Wang et al. 2005). Similarly to EGFR, the PTEN gene is frequently 
mutated in primary GBMs (15-40% cases), but rare in secondary GBM (Tohma, Gratas et al. 
1998, Knobbe, Merlo et al. 2002, Ohgaki, Dessen et al. 2004). Mutations of PIK3CA, the 
gene encoding catalytically active component (p110α) of PI3K complex are rare and account 
for 5% in primary and 13% in secondary GBMs (Kita, Yonekawa et al. 2007).  
Findings from TCGA estimated overall frequency of alterations in the EGFR/ RAS/ NF1/ 
PTEN/ PI3K pathway in 88% of GBMs with additional findings like NF1 mutations/ 
homozygous deletions to be present in 18% of cases and PIK3R1 in 10% (Cancer Genome 
Atlas Research 2008). Interestingly, mRNA expression of PDGFR was observed in astrocytic 
tumours (all grades), however, amplification of the gene was seen only in a small subset of 
GBMs (Hermanson, Funa et al. 1992). NF1 tumour suppressor gene encodes neurofibromin, 
which acts primarily as a RAS negative regulator, but it is also involved in adenylate cyclase 
and AKT-mTOR mediated pathways (Lee and Stephenson 2007).  
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Mutations in TP53 occur more frequently in secondary GBMs (65% vs 28% in primary 
GBMs) (Ohgaki, Dessen et al. 2004, Ohgaki and Kleihues 2005). MDM2 is induced by 
wildtype TP53 (Barak, Gottlieb et al. 1994, Zauberman, Flusberg et al. 1995). In turn, 
MDM2 binds to mutant and wildtype TP53 inhibiting its ability to activate transcription 
(Momand, Zambetti et al. 1992, Oliner, Kinzler et al. 1992). MDM2 amplification appears to 
be exclusive to primary GBMs, which lack TP53 mutation (Reifenberger, Liu et al. 1993, 
Biernat, Kleihues et al. 1997), however it is not frequent, occurring in less than 15% of cases 
(Nakamura, Watanabe et al. 2001). There appears to be a significant inverse correlation 
between p14
ARF
 alterations and TP53 mutations and also between MDM2 amplification and 
TP53 mutations (Zawlik, Kita et al. 2009). The results of the TCGA study on GBMs 
estimated the overall frequency of genetic alterations in the TP53/ MDM2/ MDM4/ p14
ARF
 
pathway to be 87%, through p14
ARF
 homozygous deletion or mutation (49%), TP53 
mutations or homozygous deletions (35%), MDM2 amplification (14%) and MDM4 
amplification (7%) (Cancer Genome Atlas Research 2008).  
A CNS-specific genetic deletion of tp53 and pten in mice showed a development of a 
penetrant acute-onset high-grade malignant phenotype with a close resemblance to primary 
GBM in humans. It has been established that a dual inactivation of p53 and PTEN leads to an 
undifferentiated state with high renewal potential and drives increased Myc protein levels, 
which could be responsible for impaired differentiation and enhanced renewal of NSCs 
doubly null for p53 and PTEN and tumour neurospheres (TNSs) derived from this model 
(Zheng, Ying et al. 2008). 
RB1 protein is responsible for the control of progression through G1 into the S-phase of the 
cell cycle.  The CDK4/ cyclin D1 complex phosphorylates RB1, leading to activation of E2F 
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transcription factor, responsible for activation of genes involved in the progression from G1 
into S-phase (Sherr and Roberts 1999). Progression from one phase into the next one can be 
inhibited by p16
INK4a
 which binds to CDK4 and inhibits the CDK4/ cyclin D1 complex (Sherr 
and Roberts 1999). The CDK4 amplification, loss of RB1 and homozygous deletion of 
p16
INK4a 
are largely mutually exclusive and put together they are present in half of primary 
GBMs and approximately 40% secondary GBMs (Biernat, Tohma et al. 1997).  
GBMs also harbour structural genetic changes. Most frequent are loss of heterozygosity 
(LOH) on chromosome 10 is a common genetic alteration, which occurs in up to 80% of 
GBMs (Karlbom, James et al. 1993, Rasheed, McLendon et al. 1995, Ichimura, Schmidt et al. 
1998, Fujisawa, Reis et al. 2000, Ohgaki, Dessen et al. 2004). The deleted loci include 
10p14-15, 10q23-24 (PTEN) and 10q25-pter (Karlbom, James et al. 1993, Rasheed, 
McLendon et al. 1995, Fults, Pedone et al. 1998). Frequently deleted in GBMs is the 
chromosomal region at 9p23-24.1. It encodes a gene called PTPRD, a receptor protein 
tyrosine phosphatise with tumour suppressor function (Solomon, Kim et al. 2008, Veeriah, 
Brennan et al. 2009). LOH 22q occurs in 82% of secondary GBMs and it is characterised by 
a small 957 kb deletion of a region encoding tissue inhibitor of metalloproteinases-3 (TIMP-
3) (Nakamura, Ishida et al. 2005). 
1.6.3 Molecular pathways that drive primary glioblastoma 
Inhibitor of DNA binding 2 (Id2), a transcription factor known to regulate proliferation and 
differentiation of stem and progenitor cells, is de-repressed in adult tissue neural stem cells 
(NSCs) lacking TP53 and modulates their proliferation. Constitutive expression of Id2 in 
differentiating NSCs results in maturation resistant oligodendroglial precursor cells (OPCs), a 
cell population implicated in the initiation of glioma. Id2 overexpression leads to the 
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inhibition of the Notch effector Hey1, a bHLH transcription factor, a direct transcriptional 
repressor of the oligodendroglial lineage determinant Olig2. In vivo experiments with Id2-
enhanced NSCs in a murine model engineered to express platelet-derived growth factor in the 
CNS resulted in glioma. These findings implicated a mechanism of altered NSC 
differentiation in glioma development and showed a possible explanation behind a proneural 
subtype of GBM. These data also support the concept that cellular and molecular 
characteristics of tumour cells are linked to the transformation of distinct subsets of adult 
tissue progenitors (Havrda, Paolella et al. 2014). 
A statistical approach to identify potential driver mutations in GBM was established to 
narrow a gap between known genetic changes, which occur in GBM and the unknown 
consequences of many of these mutations. The integrated analysis of copy number variations 
and somatic mutations unravelled the landscape of in-frame gene fusions in GBM. Mutations 
and deletions lead to disruptions of LZTR1, encoding an adaptor of CUL3-containing E3 
ligase complexes. LZTR1 restrains the self-renewal and growth of glioma spheres that retain 
stem cell features. Loss-of-function mutations in CTNND2 are associated with the 
transformation of glioma cells along the mesenchymal phenotype. Recurrent translocations 
fusing the coding sequence of EGFR to several partners were also reported. EGFR-SEPT14 
gene fusion is the most frequent functional gene fusion in human glioblastoma. It leads to 
STAT3 signalling activation and confers mitogen independence and sensitivity to EGFR 
inhibition (Frattini, Trifonov et al. 2013).  
The PDGF family of proteins was extensively studied (Westermark and Wasteson 1976, 
Andrae, Gallini et al. 2008). Human PDGF-AB was isolated from platelets by Carl-Henrik 
Heldin in 1979 (Heldin, Westermark et al. 1979).  It includes a number of PDGF proteins, 
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PDGF-A, -B, -C, -D. These molecules function as dimers, thanks to the presence of 
PDGF/VEGF homology domain, which forms intra- and inter-molecule disulphite bridges. 
Five dimers were observed: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and –DD. 
(Fredriksson, Li et al. 2004). They act through two cell surface tyrosine kinase (RTK) 
receptors, named PDGFRα and PDGFRβ, which have a common domain structure including 
a split intracellular tyrosine kinase domain and five extracellular immunoglobulin (Ig)-like 
domains (Claesson-Welsh 1994). When a receptor binds its respective ligand a hetero- or 
homodimerization of receptors occurs, which leads to transphosphorylation of the 
intracellular domains and activation of the receptor. Intracellular mediators then dock to 
phosphotyrosine residues in the receptor, causing activation of downstream signalling 
pathways.  
Presence of PDGF was confirmed in human clonal glioma cell lines (Nister, Heldin et al. 
1982, Nister, Heldin et al. 1984). Experiments using U-343 MGa glioma cell line showed 
clonal variation in PDGF secretion and in capacity of glioma cells to bind 125I-PDGF 
(Nister, Heldin et al. 1986), which is a radioiodinated purified platelet-derived growth factor 
(Bowen-Pope and Ross 1982). Interestingly, the growth rate correlated with the amount of 
PDGF produced, with immature cells secreting highest level of this ligand and glia-like cells 
showing highest level of 125I-PDGF binding capacity.  
Expression of PDGF and its receptors suggests the presence of autocrine and paracrine 
stimulatory loops in human gliomas (Hermanson, Funa et al. 1996, Lokker, Sullivan et al. 
2002).Infusion of PDGF was sufficient to arrest production of neuroblasts and induce 
proliferation of B cells in the SVZ, which led to formation of hyperplasias with some 
characteristics of gliomas (Jackson, Garcia-Verdugo et al. 2006). PDGF and its respective 
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receptors are frequently co-expressed in gliomas suggesting an autocrine loop mechanism. A 
study using retrovirus coding for the PDGF B-chain showed its ability to induce brain 
tumours in mice. The resulting tumours coexpressed PDGF B-chain and PDGFRα mRNA, 
explained by the autocrine mechanism of transformation, and showed consistent expression 
of Nestin, suggesting that they were derived from immature neuroglial progenitors (Uhrbom, 
Hesselager et al. 1998). When treated with CGP 57148B, a specific PDGFR tyrosine kinase 
inhibitor, the autocrine receptor activation was blocked, almost completely inhibiting cell 
proliferation (Uhrbom, Hesselager et al. 2000).  
Primary brain tumours can be induced by murine intracerebral injection with avian 
recombinant retroviruses, which contain different oncogenes, into mice which are genetically 
engineered to be susceptible to retroviral gene transfer. This approach targets specific cell 
types in the brain and allows for a creation of tumour models, which are histologically similar 
to human tumours (Uhrbom and Holland 2001). This system was used to investigate the 
effect of PDGF-B when combined with other proteins, including INK4a-ARF and p53. When 
either of the tumour suppressor genes was deleted together with retrovirally expressed PDGF-
B, a decrease in PTEN levels and increased Akt phosphorylation were observed   
(Hesselager, Uhrbom et al. 2003). 
1.6.4 Current treatment  
First line adjuvant treatment for GBMs is still dominated by cytostatic agents and 
radiotherapy. New approaches using targeted intervention with inhibitors of neo-angiogenesis 
and growth factor receptors gain recognition. Temozolomide (TMZ), an alkylating agent, and 
a concurrent radiotherapy compose a first-line adjuvant therapy for GBM patients (Hunter, 
Smith et al. 2006, Stupp, Hegi et al. 2007). Addition of temozolomide to radiotherapy 
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improves survival of newly diagnosed GBM patients, causing minimal additional toxicity 
(Stupp, Mason et al. 2005, Chamberlain, Glantz et al. 2007, Dall'oglio, D'Amico et al. 2008).  
First generation of TKIs did not bring expected results, as in vitro growth of glioma lines was 
not affected. Newer drugs seem to struggle in the clinical trial setting (Dresemann, Weller et 
al. 2010).  Analysis of tumour explants identified two different types of glioma cultures, type 
A and type B. Type B cultures had mesenchymal features and responded to mono-treatment 
with imatinib, a PDGFR inhibitor. Type A showed stem cell-like features, self-renewal in 
vitro, formation of neurospheres and in vivo tumour growth and did not respond to mono-
treatment. Resistance of type A cells was correlated with expression of SOX2 (Hagerstrand, 
He et al. 2011). Expression of SOX2, OCT4, KLF4 and NANOG, transcription factors able 
to induce pluripotent stem cells (iPS cells) (Takahashi and Yamanaka 2006), was shown in 
high-grade human glioma tissues (Holmberg, He et al. 2011). This could possibly explain 
resistance to TKIs and give a new direction in treatment, targeting stem cell-like 
compartment of the tumour, either by killing it, or leading to its differentiation and sensitising 
to other agents, which can kill more mature cells.  
Infiltrative nature of GBM poses one of the biggest hurdles for the therapy prognosis. 
Tumour cells interact with the surrounding normal tissue leading to expression of CD95 
ligand. Binding of CD95 ligand to CD95 on GBM cells recruits the Src family member Yes 
and the p85 subunit of phosphatidylinositol 3-kinase to CD95, which signal invasion via the 
glycogen synthase kinase 3-beta pathway and subsequent expression of matrix 
metalloproteinases. A blockade of CD95 activity reduces the number of invading GBM cells 
(Kleber, Sancho-Martinez et al. 2008). Studies involving CD95 inhibitor APG101, which is a 
glycosylated fusion protein consisting of the extracellular domain of human CD95 and the Fc 
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domain of human IgG1, showed a good safety and tolerability profile in a clinical trial with 
healthy volunteers. APG101 blocks the interaction between CD95 and its cognate ligand 
CD95L (Tuettenberg, Seiz et al. 2012).  
1.6.5 Cancer stem cells and differentiation therapy  
GBM tumours are composed of phenotypically heterogeneous populations of cells, which 
show variation in morphology, proliferation potential and ability to initiate tumour growth 
(Dick 2008). Heterogeneity of GBMs was recognised and is a subject of discussion 
(Shackleton, Quintana et al. 2009, Bonavia, Inda et al. 2011). Two models have been 
proposed to explain tumour heterogeneity. The hierarchical model predicts that tumours arise 
from stem cell-like precursor cells, which in the process of normal 
developmental/differentiation pathways generate non-malignant progeny. The stochastic 
model states that tumours arise as a biologically homogenous group of cells i.e. all cells are 
equally malignant. In the stochastic model, random fluctuations in gene expression or 
acquisition of genetic differences are expected to underlie tumour heterogeneity. Thus, any 
cell in this model has a potential to initiate tumour formation due to accumulation of DNA 
mutations (Dick 2009). It is quite likely that different models apply to different cancers, and 
even within the same patient at different stages of tumour progression, as for example 
melanoma has high levels of CSCs (Quintana, Shackleton et al. 2008).  
The idea of cancer stem cells gained recognition when a study of human acute myeloid 
leukaemia identified a population of CD34-positive CD38-negative cells, which drive 
proliferation of the tumour (Lapidot, Sirard et al. 1994). Interestingly, they showed that 
CD34-positive/CD38-positive and CD34-negative cells do not possess this ability. CSCs in 
other tumours were then also identified. A limiting dilution assay identified a population of 
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CD44-positive/CD24-negative/lin-negative cells, which when engrafted in SCID mice and 
showed tumorigenic potential (Al-Hajj, Wicha et al. 2003). Similar studies were performed 
for colorectal cancer (Dalerba, Dylla et al. 2007), colon cancer (O'Brien, Pollett et al. 2007), 
pancreatic cancer (Li, Heidt et al. 2007), liver cancer (Yang, Ho et al. 2008), prostate cancer 
(Wang, Kruithof-de Julio et al. 2009), and other cancer types. Interestingly, a study in human 
pancreatic cancer showed potential to distinguish distinct CSCs populations responsible for 
tumour growth and metastatic activity (Hermann, Huber et al. 2007).  
The cancer stem cell hypothesis states that only a small fraction of tumour cells has the 
potential to self-renew and initiate tumours when transplanted into immunocompromised 
mice. Cancer stem cells are thought to be responsible for maintenance and origin of solid 
malignancies, as they share properties of stem cells, the ability to self-renew and to 
differentiate into mature cell types (Sell 2004, Clarke and Fuller 2006, Vescovi, Galli et al. 
2006). This idea was reinforced by a breast cancer study, where tumorigenic cells were 
identified based on their marker expression (Al-Hajj, Wicha et al. 2003) and in brain tumours 
(Galli, Binda et al. 2004, Huntly and Gilliland 2005)  showing that stem cell characteristics of 
tumour cells can be induced by growth conditions (Ignatova, Kukekov et al. 2002). 
The origin of cancer stem cells and their relation to normal tissue stem cells remains under 
investigation (Sanai, Alvarez-Buylla et al. 2005). Brain cancer stem cells were shown to 
express a cell surface marker CD133, which was initially associated with neural stem cells 
(Singh, Clarke et al. 2003, Singh, Hawkins et al. 2004). Glial progenitors in adult white 
matter with overexpressed PDGF form tumours, which closely resemble human GBMs 
suggesting their potential role in tumour development and maintenance. SVZ progenitors 
were infected with a retrovirus expressing both PDGF and GFP. At day three post injection 
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(dpi), proliferation of PDGFRα-positive progenitors was seen in the SVZ and the white 
matter around the injection site. By day ten, rats developed diffusely infilitrating tumours, 
which resembled GBMs. Both infected and uninfected PDGFRα-positive cells were 
proliferating, suggesting that PDGF acted via both autocrine and paracrine signalling 
(Assanah, Lochhead et al. 2006). In vivo transplantation assays demonstrated that full 
progressed tumours require PDGF-B to overcome cell-cell contact inhibition and to confer in 
vivo infilitrating potential on tumour cells (Calzolari, Appolloni et al. 2008).  
CD133, also known as prominin, is considered a stem cell marker in both normal and cancer 
tissues. Cells positive for CD133 appear to have potential to self-renew, proliferate and 
differentiate (Singh, Clarke et al. 2003). In vivo studies investigating the tumour-initiating 
potential of CD133-positive cells showed mixed results with some stating that only these 
cells are capable of tumour initiation (Singh, Hawkins et al. 2004) with others showing 
similar potential in CD133-negative cells (Joo, Kim et al. 2008). CD133-positive cells show 
resistance to radiotherapy and chemotherapy (Bao, Wu et al. 2006, Liu, Yuan et al. 2006). 
When isolated, the CD133-positive and CD133-negative populations have differential 
molecular profiles and growth characteristics (Beier, Hau et al. 2007). Interestingly, CD133 
expression is associated with neurosphere formation only in primary GBMs and not in 
secondary GBMs suggesting possible different cells of origin in these tumours (Beier, Hau et 
al. 2007). CD133-positive GBM cancer stem cells are radioresistant and preferentially 
expanded in hypoxic conditions. Possible use of radiosensitizers in combination with 
therapies targeting this characteristic of GMB cancer cells could lead to improvements in PFS 
(Sheehan, Shaffrey et al. 2010). 
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Glioma stem cells contribute to radioresistance of the tumour mass by an increase in DNA 
repair capacity and preferential activation of the DNA damage checkpoint response. The 
CD133-positive cells survive ionizing radiation better when compared to the tumour mass, 
both in vitro and in brains of immunocompromised mice. Interestingly, the radioresistance of 
these cells can be reversed by inhibition of Chk1 and Chk2 checkpoint kinases (Bao, Wu et 
al. 2006).  
If GBMs are driven by cell with stem cell characteristics, then activation of specific 
differentiation pathways in cancer stem cells could lead to a loss of their stem cell properties, 
making tumours more sensitive to cytotoxic treatment or simply preventing their further 
growth. Bone morphogenetic proteins were shown to inhibit the tumorigenic potential of 
human brain tumour-initiating cells (Piccirillo, Reynolds et al. 2006). In particular, BMP-4 
shows the strongest effect, reducing the number of tumour-initiating cells in human GBMs, 
through activation of Smad signalling cascade. BMPs are able to increase expression of 
neural differentiation, without affecting cell viability, which was presented as a decrease in 
CD133-positive population size and reduction in clonogenic ability (Piccirillo, Reynolds et 
al. 2006).  
Brain CSCs, similarly to NSCs are located in a proximity of blood vessels, also in hypoxic 
areas (Seidel, Garvalov et al. 2010) and this may provide an important niche to sustain 
immature features (Gilbertson and Rich 2007). A neuronal cell adhesion molecule, called 
L1CAM, is expressed in gliomas. When CD133-positive L1CAM-positive cells were 
cosegregated and targeted with lentiviral-mediated short hairpin RNA (shRNA) the 
neurosphere formation was disrupted and proliferation reduced. L1CAM knockdown reduced 
Chapter 1  Introduction 
56 
 
expression of Olig2 and increased levels of p21 (WAF1/CIP1) in CD133-positive glioma 
cells (Bao, Wu et al. 2008).  
1.6.6 In vitro culture of GBM stem cells 
A link between neural stem cells and their malignant counterparts (cancer stem cells) was 
hypothesised as a hierarchical process of differentiation was suggested for GBM and other 
solid tumours, where a subpopulation of stem cell-like or tumour initiating cells (TICs) are 
responsible for the maintenance of the tumour. Only by targeting TICs would it be possible to 
avoid disease recurrence following debulking of the tumour mass. Even if not necessarily 
arising from neural stem cells, the TICs are reminiscent of neural stem cells in their biology 
and their role in maintaining the tissue of a tumour. Forcing differentiation of brain cancer 
stem cells may therefore have therapeutic value. In vitro expansion of putative GBM cancer 
stem cells could be a valuable tool to understand processes behind their cellular behaviour 
and to create novel cancer treatments.  
A combination of EGF and FGF-2 on an adherent substrate is important for propagation of 
both mouse and human NS cells without spontaneous differentiation or cell death (Conti, 
Pollard et al. 2005, Sun, Pollard et al. 2008). A similar approach was used to establish glioma 
stem cell lines (Pollard, Yoshikawa et al. 2009). Primary cultures presented diversity of 
cellular phenotypes, being a mixture of putative stem cells, progenitors and differentiated 
cells. The heterogeneity was, however, reduced after 2-3 passages. A number of cell lines 
from histopathologically distinct types of tumour were established, including GBM (G144, 
G166, and GliNS2), GC-GBM (G179) and an anaplastic oligoastrocytoma (G174). The 
established lines express markers of NS cell/neural progenitors, like Vimentin, Sox2, Nestin, 
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3CB2. However, some variation between the lines was observed with G144 and G179 lines 
being highly motile and showing dynamic changes in cell shape.  
The adherent GNS lines offer a number of advantages like increased proliferative expansion 
of glioma stem cells when compared side-by-side to the neurosphere culture. EGF and FGF-2 
fully suppress differentiation of these cells to oligodendrocytes (O4-positive cells), or 
neurons (Tuj-1-positive cells). In the absence of growth factors G144 and G179 GNS begin 
to differentiate, with G144 being characterised by a significant number of O4-positive or 
CNPase-positive oligodendrocyte-like cells within one week. On the other hand, G179 
mostly generates Tuj-1-positive cells. Interestingly, G166 line continues to proliferate in the 
absence of growth factors without any apparent differentiation.  
In the presence of BMP-4 GNS lines G144 and G179 change morphology within seven days 
of treatment. Cells express high levels of GFAP, with a small population of Doublecortin-
positive neuronal-like cells, which is also observed in human foetal NS cells. G166 line has a 
lower frequency of GFAP expression showing that a capacity to differentiate, efficiency and 
lineage choice vary between the cell lines (Pollard, Yoshikawa et al. 2009).  
Human GNS lines are suitable for a chemical screening application. They offer a number of 
advantages over the neurosphere drug screening. Most importantly, it is possible to quantify 
cell proliferation, which is more difficult in the suspension culture, because of variable cell 
death. Fusion of neurospheres can interfere with analyses based on the sphere number or their 
size. Also, a real-time monitoring of cellular activity is possible only in the adherent GNS 
culture. Pollard et al. used GNS lines to screen 450 compounds from the NIH Clinical 
collection using G144, G166 and G179 GNS lines and identified 38 compounds which had a 
significant cytotoxic or cytostatic effect on at least one line. Line-specific effects were 
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observed for 15 compounds, which was consistent with the individualized phenotypes of 
GNS cells (Pollard, Yoshikawa et al. 2009). Danovi et al. used GNS lines to screen a library 
of 160 small molecule kinase inhibitors and identified a compound called JNJ-10198409, 
which induced a mitotic arrest at prometaphase in GNS cells, but not in human NS cells 
(Danovi, Folarin et al. 2013). These studies validated adherent GNS culture as a tool for 
chemical screening application. 
1.7 High-content chemical screening 
1.7.1 Background 
Two terms, high content screening (HCS) and high throughput screening (HTS) are 
frequently confused. While in HCS a rich phenotypic information is extracted from either 
fixed or live cells, the HTS allows for assessment of hundreds of thousands of compounds 
using a single biochemical assay. HCS includes any method used to analyse cells with a 
simultaneous readout of multiple phenotypic parameters (Gasparri 2009).  Widely used in 
drug discovery, but also in biological research, HCS allows for the observation of 
morphological changes and variations in the production of phenotypic markers, which could 
be measured with the use of immunostaining or, if transgenic reporters are used, a direct 
measure of fluorescence reporters e.g. green fluorescent protein (GFP) in live cells. 
There are two main goals, which every HCS method aims to achieve. First, acquisition of 
spatially or temporally resolved information on an event and second, its automatic 
segmentation and quantification. In order to achieve these goals HCS incorporates automated 
microscopes (spatially resolved instruments) and fluorescent measurements (temporal 
resolution).  Use of automated systems and software allows for rapid and unbiased analysis of 
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data. The image analysis software can be supplied with instruments needed for the 
experiments, however it is not uncommon to standardise multiple experiments and 
instruments to use a single platform.  
Considering the large scale of the analysis it is common to identify multiple potentially 
interesting molecules based on their effect on cell phenotype, which could be described as 
desired e.g. increase in protein expression, undesired e.g. cytotoxicity or unexpected e.g. 
change in morphology or complete inhibition of protein expression.  
Increasingly the use of liquid handling devices combined with automated image acquisition 
and processing are crucial for the efficient data collection and analysis and can now be 
carried out in individual academic laboratories.  Technological advances that led to the 
development of high-throughput microscopy spurred the concept of HCS as a tool bridging 
depth and throughput of biological experiments.  Hardware improvements, like auto-focusing 
and sample positioning and development of image analysis software, position HCS as one of 
the new crucial methods in biological research and a mainstream technology in 
pharmaceutical industry. 
1.7.2 Chemical versus genetic screening 
HCS is an alternative to a genetic approach to analyse biological systems. The genetic 
approach entails determining the phenotypic consequences of mutations in genes and 
ordering genes into functional pathways (Stockwell, Haggarty et al. 1999). This approach is 
widely used in a number of study organisms including fruit flies, nematodes, yeast, plants, 
zebrafish and mice (Nadeau and Dunn 1998). With whole organism models like mice there 
are, however, some limitations, which can include the cost of space, animals, their long 
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generation time, small litter size and the difficulty inherent in identifying and mapping 
recessive mutations. In addition, many gene products can be essential, redundant or expressed 
in a tissue-specific or a temporal manner. Some of these problems can be minimised by the 
use of tissue culture, which can still provide a useful tool for a study for understanding of 
physiological and developmental pathways in a mammalian system (Xiong, Battaglino et al. 
1998).  
Use of libraries of small molecules, which can alter protein function directly, has a potential 
to overcome limitations of genetic analysis. Small molecule approach in cell-based assays 
can lead to a specific functional alteration in all copies of gene product, making it analogous 
to an inducible dominant or homozygous recessive mutation. Another similarity lies in 
possibility to identify target sequences. As mutation sites can reveal functionally relevant 
gene coding sequences, it is possible to identify functionally relevant protein residues based 
on small molecule mechanism of interaction (Fenteany, Standaert et al. 1995). 
One of the most important differences between small molecules and mutations as a source of 
phenotypic variation is the fact that small molecule-induced changes, unlike genetic 
mutations, are usually not hereditary. The perturbations from small molecules are then 
usually reversible and conditional, as small molecules can be added or removed from the 
experiment at will.  
1.7.3 Target identification 
The goal of the small molecule screening is the identification of a compound which would 
elicit its effects at low nM concentrations, meaning high specificity and affinity. 
Unfortunately, this is rarely the case with low uM concentrations considered to be a good 
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outcome. In order to improve potency, chemical analysis is employed leading to 
modifications in compound structure. However, this process can be expensive and requires 
time, making it harder to rival natural products which are readily available. Identification of 
target pathways or influenced molecules is a rate-limiting step in HCS. In the past targets of 
small molecules were identified by affinity methods or candidate-based approaches.  Thus, 
identification of a ‘hit’ or ‘lead’ compound is only the first step in drug development 
pipelines. 
There are multiple new methods to identify small molecule molecular targets. One of the 
methods involves preparation of radiolabeled derivatives of the small molecule and 
determining the molecular targets that are labelled by these radioactive probes (Kwon, Owa 
et al. 1998). Another approach is to use a ‘three-hybrid’ transcriptional activation system. It 
anchors a derivative of the active ligand for display against a library of cDNAs, which are 
fused to a transcription activation domain (Licitra and Liu 1996, Borchardt, Liberles et al. 
1997) Also, expression cloning can be used to find target within a small pool of proteins 
(King, Lustig et al. 1997). In affinity methods small molecules are tethered to a solid support 
with cell extracts being passed over them, looking for a specific small molecule-protein 
binding. 
One way to circumvent the difficulties of defining targets of novel small molecules is to work 
with panel of compounds with known activities and targets/pathways.  Many libraries of 
known inhibitors/agonist  compounds are commercially available, with some laboratories 
creating their own diverse libraries with compound annotations and effect measured scoring 
system to identify commonly known and new potentially interesting molecules (Root, 
Flaherty et al. 2003).  
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A combined approach of comparing small molecule and RNAi phenotypes can also provide 
valuable information (Eggert and Mitchison 2006). This method is based on the assumption 
that if RNAi and small molecule treatments give a similar phenotype it is likely that a protein 
target is the same. In a study of proteins involved in cytokinesis, a genome-wide RNAi and 
small molecule screens were performed in parallel allowing for identification of a small 
molecule inhibitor of the Aurora B kinase pathway (Eggert, Kiger et al. 2004). It is important 
to mention that this approach also has some limitations as the phenotype of small molecule 
inhibition might be different from an RNAi phenotype, where protein is depleted from the 
cell (Eggert, Field et al. 2006). Two additional approaches to identification of small 
molecules which are biologically active include design of small molecules to interact with 
active sites of proteins, which structures are understood (Blundell 1996), and screening 
methods  developed to identify novel protein-small molecule interactions (Borchardt, 
Liberles et al. 1997, Huang and Schreiber 1997).  
1.7.4 HCS applications  
HCS has applications in a wide range of study fields. Kinetic HCS studies usually measure 
calcium fluxes, cytotoxicity, and receptor internalization, while studies of cellular processes 
like proliferation, differentiation or motility are predominantly performed as fixed endpoint 
assays. This however, is changing with the development of new tools allowing cell tracking 
and ‘learning’ software capable of identifying different cell types and states, like progenitors 
or differentiated cells. Turning standard biological methods into HCS can be also seen. The 
wound-healing assay measuring epithelial cell motility was scaled up to 384-well format to 
screen for cell migration defects (Yarrow, Perlman et al. 2004, Yarrow, Totsukawa et al. 
2005). In this case HCS allowed for a simultaneous measurement of rate changes during 
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closure of an individual wound, motility and relative morphology of cells and trailing cell 
sheet.  
The applications of HCS include drug discovery where tens of thousands of molecules are 
analysed in search of clinically relevant drugs. Field of chemical genetics uses HCS to study 
genome and gene function by identifying small molecules that regulate gene activity. This 
could be very beneficial, leading to targeted chemical knockout of proteins, in case knockout 
mice cannot be made because of protein involvement in development and growth, causing 
lethality in knockout embryos.  Studies using chemical knockout could further our 
understanding of gene functionality in development and adult organisms.   
HCS is used in a variety of study models, including primary cells and whole organisms e.g. 
zebrafish (Zon and Peterson 2005) and C. elegans nematodes (Fraser, Kamath et al. 2000). 
Use of whole organisms allows for identification of functional data, which can show direct 
promise in curing some of the diseases e.g. preventing cardiovascular defects caused by a 
genetic mutation as it was shown in the zebrafish model (Peterson, Shaw et al. 2004). A 
genome-wide deletion mutant screen in yeast identified nine missing components of the 
phosphate-responsive signal transduction PHO pathway (Huang and O'Shea 2005). Another 
example is a large-scale automated screening of a mammalian U2OS osteosarcoma cell line, 
where individual overexpression of 7364 microarrayed cDNAs led to identification of genes 
involved in cell proliferation under a variety of growth conditions (Harada, Bower et al. 
2005).   
HCS applications can be seen as both fixed endpoint assays and time-lapse assays, with a 
fixed point approach being potentially a high throughput screening method. Depending on the 
goal of the experiment, it is possible to prepare a whole time-course by preparing multiple 
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plates processed over time or define half time of cellular processes of interest in the 
beginning of an experiment and then set the fixation time accordingly (Giuliano, Haskins et 
al. 2003). Incorporation of an environmental chamber into the HCS reader system allows for 
live HCS applications. This can be accomplished with the use of specific devices, e.g. a live 
cell imaging system called Incucyte, or by applying add-ons to an endpoint HCS device 
(Giuliano, Haskins et al. 2003, Taylor and Giuliano 2005). In this case, full kinetic 
measurements can be made, before, during and after the treatment, providing a full range of 
biological information (Abraham, Taylor et al. 2004).  
HCS contrasts with traditional cell-based methods like plate-based reporter assays, where a 
readout observed is an average of thousands of cells, as HCS acquires morphometric and 
functional information from collections of individual cells.  This allows for a more in-depth 
analysis and observations of variation within cell populations in situations when only a 
subpopulation of cells is affected. This could be due to heterogeneity of the cell population, 
or due to e.g. variable transfection efficiency.  
The most common methods include labelling proteins with fluorescent tags, e.g. GFP fused to 
endogenous protein or the use of fluorescent antibody, followed by automated image analysis 
allowing to understand the effect of a substance of interest on  a given protein level. It is 
possible to tag multiple proteins at once thanks to their different absorption and emission 
maxima and measure different cell characteristics at once. Another less common method 
involves use of small molecule fluorescent probes. 
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1.7.5 Technical aspects of HCS 
A range of parameters need to be optimised in order for successful HCS to be carried out. A 
typical mammalian cell, which is attached and spread on a microplate bottom can have a size 
of 20-50 um across and a nucleus of about 5-10 um in diameter. One hundred of these cells, 
as a confluent layer, occupy an area of about 400 um on a side. This however, depends on the 
cell type, plating density, and the amount of spreading. HCS platform design has to allow for 
acquisition of images with sufficient contrast, resolution, and signal-to-noise ratio, which will 
enable image algorithms to extract features of interest. Parameters like maximum cell density 
have to be considered, e.g. a cell-spreading assay requires subconfluent cells, whereas high 
confluency is better for receptor activation assays.  In order to achieve an adequate level of 
statistical significance it might be necessary to analyse 100 or up to 1000 or more cells, 
which occupy an area as large as several square millimetres. For most applications an HCS 
system with a field of view of several square millimetres and a resolution around 1 um is 
considered acceptable (Gough and Johnston 2007).  
A new emerging field of HCS using time-lapse movies of cells expressing GFP-tagged 
proteins faces its own challenges. Currently, a storage and analysis of movies is the limiting 
step for this approach. A limited number of studies were performed, where a systematic 
annotation of experimental videos was used to develop a phenotypic profiling system, which 
showed a high correlation with cellular processes and biochemical pathways enabling for 
prediction of new functions of previously uncharacterised genes (Sonnichsen, Koski et al. 
2005). 
One of the most essential aspects of a HCS system is a reliable autofocus system.  A slightly 
soft focus even 1% of the time can affect screening results.  For the HCS application a 
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reliable autofocus has to deal with a number of challenges. It has to be fast, as even 1s/well 
adds more than 6 minutes to the scan time on a 384-well plate, and offer precise focus within 
a few microns, depending on the objective used. Another challenge is microplates, which 
bottoms are universally bowed, typically by more than a hundred microns corner to centre. 
This can affect the z-position of the well, leaving a variation from one well to another as big 
as 50um or more. Microplates, their thickness and surface quality have to be also considered, 
with glass-bottom plates providing a much smoother and uniformly thick substrate. However, 
their bottom is still bowed and the plates are still considered too expensive for a routine used 
in most laboratories. 
Software is an important component of any HCS application.  The automated imaging 
platform software must offer a possibility of visual data mining (Berlage 2005). A level of 
confidence has to be established in the beginning of every run to validate that all systems are 
functioning properly. The software must be able to monitor and display the progress of the 
run in real time, e.g. checking progress on a plate level, plate views with some defined 
representation in a form of confluency or a heat map and image views of fields already 
captured.  The software has to be interactive enough to allow user to assess the quality of the 
experiment and programmed analysis.  
Every HCS imaging system has to meet a minimum of requirements like sufficient resolution 
and sensitivity to capture and analyze the cellular features of interest, spectral channels to 
distinguish multiple fluorescent labels, a field of view large enough to image multiple cells, 
adequate speed to meet the needs of the planned screening volume and flexibility to address a 
wide range of assay requirements. However, the optimum design for a particular assay 
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requires an understanding of the experimental goals and the relationships between these 
requirements (Gough and Johnston 2007). 
One of the biggest challenges of image-based screenings is the analysis of data. A typical 
screening will generate gigabytes or even terabytes of data, which have to be extracted, 
saved, analysed and understood.  Cell profiler and Cell profiler analyst, software produced by 
the Broad Institute, is open-source software commonly used for high content screening 
applications (Carpenter, Jones et al. 2006, Jones, Kang et al. 2008, Logan and Carpenter 
2010). It enables to quantitatively measure phenotypes from thousands of images 
automatically. A simplified interface presents advanced algorithms in a form of individual 
modules which, when placed in a sequential order, form a pipeline. The software can measure 
multiple characteristics including: cell number, percentage of dye- or fluorescent tag-positive 
cells, cell size, texture and fluorescence intensity. The alternative to Cell profiler is java-
based software called ImageJ, which can handle small scale processing and analysis. This 
tool is suitable for novice users allowing for basic segmentation and cell quantification, but it 
does not yet provide scalability necessary for HCS.   
Currently, relational databases are used to facilitate image analysis, although storing only 
meta-information about images in a database with actual images being stored as ordinary files 
is considered to be an efficient method. Open Microscopy Initiative (OME) and open-source 
academic consortium provide databases for image handling.  
Quantitative phenotypic information has to be extracted from the images, which typically 
requires interaction of screeners with experts in the field of image analysis. Typical analysis 
starts by identification of individual cells and regions of interest, e.g. nuclei or organelles in 
case subcellular information is needed in order to understand the biological function. 
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Subsequently, other parameters like fluorescence intensity, shape, size and texture are 
measured. It is possible to take over ten measurements for a single object (Perlman, Slack et 
al. 2004). 
1.8 Goal of the project 
The specific aim of this project was to identify small molecules that can direct or stimulate 
differentiation of neural stem cells. The long-term goal is to make use of this knowledge and 
reagents to force differentiation of human GBM stem cells with a view to develop new types 
of differentiation therapy. Oligodendrocyte differentiation is often observed in primary GBM 
and is therefore an attractive lineage to focus on. 
A transgenic PDGFRα ‘knock-in’ reporter strain of mice (B6.129S4-Pdgfratm11(EGFP)Sor/J) was 
obtained courtesy of Dr Philippe Soriano (Hamilton, Klinghoffer et al. 2003). These mice 
express the H2B-eGFP fusion gene from the endogenous PDGFRα locus (Figure 6). 
Homozygotes for this knock-in targeted mutation have an embryonic lethal phenotype and 
fail to survive beyond embryonic day 15.5, exhibiting abnormal placenta development and 
vasculature.  In this project I made use of these reporter mice to establish a novel panel of 
mouse NS cell reporter lines, use these in HCS and identify some of the key molecular events 
controlling the process of NS cell lineage choice and differentiation, and associated small 
molecule inhibitors that modulate NS cell differentiation.  
The main objective of this work was the identification of cell permeable small molecules that 
can direct the differentiation of NS cells.  There are four major goals: 
1) Establish and validate PDGFRα-GFP reporter NS cell lines. 
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2) Use these reporter cells lines in chemical screens (HCS). 
3) Identification and validation of small molecules that influence NS cell differentiation. 
4) Assessment of whether these agents influence GBM-derived NS cells self-renewal 
and differentiation.  
It is anticipated that the use of in vitro screening platform can provide insights into 
molecular mechanisms underlying NS cell differentiation and broaden our understanding 
of the differentiation process. Longer term we hope our findings will impact clinical 
treatment of GBM through identification of new therapeutic agents and pathways. 
Furthermore, a direct and efficient differentiation protocol could allow for improved 
control of NS cell differentiation in the laboratory for applications in new types of 
regenerative medicine. 
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Figure 6. Expression patterns of PDGFRα (αGFP) in embryonic and adult tissues. Adapted from (Hamilton, 
Klinghoffer et al. 2003); (A) Expression in polar trophectoderm of E4.5 blastocysts. Bottom panel, visible light; 
top panel, UV. (B) Expression in extraembryonic ectoderm of an E6.5 embryo. Top panel, UV; bottom panel, 
visible light. Arrows denote the boundary of embryonic and extraembryonic tissues, and Reichert's membrane 
was not removed. (C) Whole-mount E10.5 embryo αGFP/+. (D) Magnification of the caudal somite. (E) E13.5 
littermates. Left embryo, αGFP/+; right embryo, αGFP/αGFP. Expression in whole-mount E18.5 organs, lung (F), 
stomach (G, top portion), and transverse section of adult stomach in the glandular region (G, lower portion). (H) 
Sagittal section of adult heart. (I) Whole-mount adult eye. (J) Sagittal section of ribs and spinal cord of an E16.5 
αGFP/+embryo. (K) E18.5 αGFP/+ transverse section through ribs. Whole-mount (L) and transverse section (M) of 
an E14.5 αGFP/+ placenta visualized under fluorescence. ICM, inner cell mass; NT, neural tube; S, somites; V, 
ventricle; A, aorta; L, lens; R, ribs; P, perichondrium; La, labyrinth; ST, spongiotrophoblast layer; CA, 
chorioallantoic layer; U, umbilical cord. 
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Chapter 2 Methodology 
2.1 Culture of NS cells and differentiation protocols 
2.1.1 Mouse NS cell lines 
Mouse primary NS cell cultures were previously established from E17.5 forebrain from an 
established transgenic B6.129S4-Pdgfra
tm11(EGFP)Sor
/J mouse strain (Hamilton, Klinghoffer et 
al. 2003) and were termed PG1 (H2B:GFP expressed from PDGFRα locus).  I established 
twelve different clonal cell lines from these initial cultures (termed, PG1-1 through 12). 
Previously characterised wild-type NS cells, Cor3-4, were used as a control (Pollard, Conti et 
al. 2006). 
2.1.2 Proliferation 
Cells were cultured in homemade NS cell ‘complete media’ consisting of DMEM/F-12 
supplemented with glucose, NEAA, Pen/Strep, HEPES, 75 mg/ml BSA solution, 2-
mercapthoethanol, B27 and N2 supplements. A sterility check was performed using Tryptose 
solution 1:1. Cells were expanded by addition of 10 ng/ml EGF and 10 ng/ml FGF-2. 
Adhesion of cells to the plastic surface of flasks was promoted by the addition of Laminin (1 
μg/ml) (Sigma) to the culture media. Cells were typically grown to ~80-90% confluence, 
dissociated using Accutase (PAA) and split 1:3 or 1:5 during passaging. I routinely used 
cultures <25 passage to avoid risks of accumulation of karyotypic abnormalities. 
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2.1.3 NS cell differentiation  
Mouse foetal NS cells were cultured in homemade NS cell media (see above) with 10 ng/ml 
FGF-2, 10 ng/ml PDGF-AA and laminin (EGF withdrawal). This triggers the process of 
oligodendroglial differentiation. Cells were incubated for 3-4 days in this condition at which 
point cells undergo morphological and molecular changes associated with differentiation. To 
promote full differentiation the culture media was replaced with NS cell media without any 
growth factors for the following 3-4 days (FGF-2 and PDGF withdrawal). To promote 
astrocytic differentiation mouse foetal NS cells were cultured in homemade NS cell media 
(see above) supplemented with 10 ng/ml BMP-4, leading to a consistent formation of GFAP-
positive cell population with characteristic spread morphology.  
2.2 Quantitative RT-PCR 
Qiagen RNeasy kit (Qiagen) was used for total mRNA extraction and cDNA was synthesised 
using Superscript III according to manufacturer’s instructions (Invitrogen). A LightCycler 
480 (Roche) was used for the quantitative RT-PCR. Probe-based PCRs were performed using 
the Universal Probe library (Roche). Normalisation of samples was carried out using 18S 
ribosomal RNA as a loading control. Experiments were performed in technical duplicates or 
triplicates depending on sample availability. Fold change calculations were made relative to 
undifferentiated cells. The Universal Probe Library Assay Design Center (Roche) was used 
for primer design. 
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Table 1. Primer pairs for RT-PCR 
Gene Forward primer Reverse primer 
UPL Probe 
Number 
H2B:GFP Gaagcgcgatcacatggt ccatgccgagagtgatcc 67 
PDGFRα 
(#1) 
Gaaggcaggcacatttacatc ccagtttgatggatgggagt 25 
PDGFRα 
(#2) 
Gtcgttgacctgcagtgga ccagcatggtgatacctttgt 80 
OLIG2 Agaccgagccaacaccag aagctctcgaatgatccttcttt 21 
SOX10 Atgtcagatgggaacccaga gtctttggggtggttggag 21 
FOXG1 Gaaggcctccacagaacg ggcaaggcatgtagcaaaag 4 
NG2 Cagaagggaccagctagagg gggcttctcaacgagaacat 16 
NKX2.2 Gcagcgacaacccctaca atttggagctcgagtcttgg 20 
GFAP Tcgagatcgccacctacag gtctgtacaggaatggtgatgc 67 
TUBB3 Gcgcatcagcgtatactacaa ttccaagtccaccagaatgg 104 
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2.3 Western blotting 
Lysis buffer comprised NaCl (150 mM), NP-40 (0.25%), Tris-HCl (20 mM), EDTA (2 mM) 
and NaF (1mM). Protease inhibitors were added to the lysis buffer: AEB5F (1:200), 
Leupeptin (1:1000), DTT (1:1000) and benzamidine (1:1000). A 12% gel was used for the 
protein separation and the blotting was performed using the following antibodies:  rabbit 
monoclonal PDGFRα antibody (1:500, Cell Signaling Technologies), mouse monoclonal 
GFP antibody (1:500, Sigma) and rat hybridoma anti-tubulin antibody (1:1000) as a loading 
control. ECL system (Amersham) was used for protein detection. 
2.4 Flow cytometry analysis of PDGFRα activation 
Proliferating PG1 cells were used as a negative control for GFP expression and for setting 
gates. Differentiating mouse wild-type COR3-4 cells were used as a negative control to set 
the gates as there are shifts due to differences in cell shape/size and autofluorescence during 
the differentiation process. Cells were incubated in differentiating conditions for the period of 
4 days, then dissociated with accutase and harvested. The pellet was resuspended in ‘wash 
media’ (DMEM/F12) at 2x106 cells/ml. 5 µg/ml Propidium Iodine (PI, Sigma-Aldrich) was 
added to cells ten minutes prior to the analysis. Cells were analysed on Cyan ADP Analyzer 
(Beckman Coulter) or sorted on MoFlo XDP Cell Sorter (Beckman Coulter). The flow 
cytometry data was analysed using Kaluza Analysis Software (Beckman Coulter).  1x10
4
 
cells per condition were analysed.  
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2.5 Immunocytochemistry 
Cells were washed twice with PBS and fixed in 4% Paraformaldehyde for 10 minutes at room 
temperature. Fixed cells were washed with PBST (PBS +0.1% Triton) followed by  
10-30 minutes incubation in a blocking solution (0.1% BSA + 3% goat serum). Primary 
antibodies diluted in the blocking solution were added to cells and incubated overnight at  
4
o
 C. Wash steps for 3 x 5 minutes followed by 2 x 15 minutes incubations with PBST were 
used to remove unbound antibody. Secondary goat anti-mouse or rabbit antibodies 
conjugated to Alexa flours (488, 594, or 647) (Molecular probes, 1:1000) were diluted in 
blocking solution and incubated with cells for 1 hour in the dark at room temperature. The 
removal of secondary antibodies was performed exactly as for primary antibodies followed 
by 5 minutes incubation of cells with DAPI for nuclear counterstaining (Sigma, 1:2500, 
diluted in PBST). Observation and image collection was performed under the inverted 
microscope Zeiss Axio observer Z1 (Zeiss). Images were acquired using AxioVision 4.8.2.0 
software. 
2.6 Karyotyping 
Cells were washed twice with PBS, dissociated using Accutase (PAA) and the cell pellet was 
mixed with 5 ml of 0.56% (0.075M) KCl solution for 20 minutes at room temperature 
causing cells to swell. This incubation was followed by addition of 0.5 ml of MeOH/Acetic 
Acid (3:1) (FIX solution) in which cells were spun for 5 minutes at 1100 rpm.  The pellet was 
then resuspended in 1 ml of FIX and kept on ice for 15 minutes. Metaphase spreads were 
performed by dropping 250 ul of cells on a glass slide from a height of around 30 cm. The 
slides were then rapidly dried and incubated with DAPI (diluted in PBS, 1:2500, Sigma). 
After 10 minutes incubation slides were mounted with hardmount (Vector labs) and 
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coverslips. Observation was performed using Zeiss Z1 microscope at 40X magnification. The 
modal chromosomal number was determined by counting ~40 cells in metaphase per cell 
line. 
2.7 High Content Chemical Screening 
Cells were plated in 96-well plates (Iwaki) using CyBi- SELMA (CyBio) semi-automatic 96-
fold liquid handling station at 6x10
3
 cells/well in differentiating conditions (as outlined 
above). The same device was used for the addition of StemSelect
TM
 and InhibitorSelect
TM 
libraries to the plates. For the screening a 1 in 10,000 dilution (for StemSelect) or 100 nM 
dilution (InhibitorSelect) of the original library stock was used. Cells were incubated at 37
o
C 
in INCUCYTE
TM 
Live-Cell Imaging System for the period of 3 days with images acquired 
every 3 hours. The screening experiment was repeated 4 times over a period of 6 month. Data 
was processed and analysed using CellProfiler (http://www.cellprofiler.org/) and R 2.11 
software (http://www.r-project.org/). Presented heat maps show result of a combined analysis 
of the 4 biological replicates. 
2.8 Transfection 
Cells were transfected with the pcDNF5 x-EGFPstop plasmid (NFkB GFP reporter), or 
dsRed plasmid (for mouse brain explants studies) using Lipofectamine LTX Reagent 
(Invitrogen) or Neon
®
 Transfection System (Life Technologies) according to manufacturer’s 
instructions. Cells were 70-90% confluent on the day of transfection. In case of Neon 
transfection, 2.5x10
6 
cells were resuspended in 100 ul Buffer R and gently mixed with 2ug 
DNA. For optimal transfection efficiency Neon device settings were adjusted to a Single 
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Pulse with a Voltage of 1600 and Width of 20. Stable transformants were selected using flow 
cytometry based on their expression of GFP reporter.  
2.9 Statistical Analysis 
Data are presented as mean ±SD. The statistical analysis was performed using Student T-Test 
Calculator available at http://www.socscistatistics.com/tests/studentttest/Default2.aspx .  
A p-value equal to or less than 0.05 was considered as statistically significant. Statistical 
significance was evaluated by double-sided t-test.  
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Chapter 3 Establishment and characterisation of a PDGFRα H2B:GFP 
reporter NS cell line 
3.1 Introduction 
Identification of cells with self-renewing and multipotent differentiation potential was first 
demonstrated using in vitro assays from the embryonic mouse brain (Temple 1989). Stem 
cells in the adult mammalian brain reside in two distinct anatomical sites: the subventricular 
zone (SVZ) along the lateral wall of the lateral ventricles and in the subgranular zone (SGZ) 
of the hippocampal dentate gyrus (Conover and Notti 2008).  
Cell culture of cells derived from mouse developing or adult SVZ shows that FGF-2 and/or 
EGF enables the continuous in vitro expansion of cells that retain neural stem cell 
characteristics (Reynolds and Weiss 1992, Vescovi, Reynolds et al. 1993). Neural stem cells 
in vitro give rise to all three neural lineages: oligodendrocytes, astrocytes and neurons 
(Reynolds and Weiss 1992). Such in vitro models provide a useful cellular model system to 
explore neural stem cell self-renewal and differentiation. 
Neural stem cells can also be expanded continuously as adherent cell lines that display self-
renewal and multi-lineage differentiation ability (Conti, Pollard et al. 2005, Pollard, Conti et 
al. 2006, Pollard 2013). In this thesis I use the term ‘NS cell’ to refer specifically to these 
adherent in vitro cell lines. A particular advantage of using adherent monolayer is the 
suppression of differentiation and apoptosis, enabling propagation of more pure populations 
of stem cells, and facilitating cellular phenotyping. This allowed assigning radial glia identity 
to the neurosphere-forming stem cell population with RC2, BLBP and GLAST markers 
expressed uniformly. Adherent culture is also well suited for chemical screening as individual 
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cells can be monitored and tracked (Pollard, Clarke et al. 2009). These defined culture 
conditions and homogenous populations of NS cells provide a useful cellular model system to 
explore those pathways that control self-renewal and differentiation.  
PDGFRα is one of the earliest markers of the transition from radial glia/neural progenitor to 
OPCs (Pringle and Richardson 1993). Expression of PDGFRα is necessary for this lineage 
progression (Hall, Giese et al. 1996). PDGFRα is a cell surface tyrosine kinase receptor, 
which interacts with the members of a platelet-derived growth factor family, and is 
implicated in diverse cellular processes including cell proliferation, differentiation and 
development. OPCs express PDGFRα, and expression is subsequently extinguished as cells 
transit to become mature oligodendrocytes (Ellison and de Vellis 1994). 
My first goal was to establish a useful live cell reporter to monitor the transition of NS cells 
to OPCs. This could be extremely useful for differentiation studies, with the ability to track 
OPC lineage specification through reporter activation in case of oligodendrocyte 
differentiation or inhibition indicating some alternative fate.  
3.2 Results   
3.2.1 Derivation of PG1 clonal cell lines  
The PDGFRα GFP reporter mouse strain B6.129S4-Pdgfratm11(EGFP)Sor/J was used and E17.5 
forebrain was obtained and used to establish a primary NS cell culture (S. Pollard, 
unpublished). I expanded these primary cultures (termed PG1 for PDGFRα-GFP) further 
before plating cells at clonal density to generate NS cell colonies (typically 5000 cell plated 
and left for 10-14 days for colonies to emerge). Colonies were picked into 24 well plates and 
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expanded further. 12 independent clonal NS cell lines were established (termed, PG1-1 to 
PG1-12). Three clonal lines (PG1-1, PG1-3, and PG1-5) were selected based on optimal 
adhesion to the substrate and were expanded further and characterised. Each cell line 
expressed the NS cell markers: Nestin, RC2, BLBP, OLIG2, SOX2, SOX9 with morphology 
of neural stem cells (Figure 7A). However, following metaphase spreads to determine the 
karyotype we eliminated PG1-5 from further analysis as it was aneuploid (Figure 7B).  
Differentiation potential of PG1 cells was also analysed. When treated with BMP-4 or 5% 
Foetal Calf Serum (FCS), PG1 cells expressed higher levels of GFAP, a marker of astrocytic 
lineage, consistent with previously reported NS cells. Activation of GFAP was also observed 
in PDGF and FGF-2 treated cells, but at a much lower frequency. Levels of immature neural 
progenitor markers Nestin and NG2 were downregulated using either of the differentiation 
protocols. SOX2, which was expressed by proliferating cells, appeared to be expressed by 
cells treated with PDGF and FGF-2, but not BMP-4 suggesting the BMP treated cultures 
were driven towards a differentiated state (Figure 8A).  
It has been reported that PDGFRα expression marks quiescent astrocyte stem cells in the 
forebrain. We tested PG1 cells with a combination of BMP-4 and other growth factors, 
including EGF, FGF-2, and PDGF led to identification of BMP-4 and FGF-2 to determine 
whether GFAP and GFP were ever co-expressed. We find that less than 0.15% cells were 
expressing these two molecules, which was confirmed in a immunofluorescent analysis of 
over 2,000 cells (Figure 8B and C). Therefore, the majority of GFAP cells induced in PG1 
cultures with BMP are likely post-mitotic astrocytes. 
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Figure 7. PG1 cell lines show characteristics of NS cells. (A) Live phase-contrast images and immunostaining 
reveal neural stem cell morphology and expression of neural stem cell markers in NS cell lines; both PG1 and two 
clonal line PG1-1 and -3 expressed OLIG2, Nestin, SOX2, SOX9, BLBP, and RC2; scale bars 50µm; (B) Example 
images of metaphase spreads from PG1 and two clonal lines and a table summarising karyotypes of cell lines 
tested. One clonal cell line (PG1-5) showed abnormal chromosomal number and was removed from further 
analysis. 
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Figure 8. NS cells in vitro can self-renew and differentiate into neural cell types. (A) Cells treated with a 
combination of growth factors: EGF and FGF-2 (proliferation conditions), PDGF and FGF-2 (oligodendroglial 
differentiation conditions), BMP-4 and 5% FCS (astrocytic differentiation conditions); Proliferating cells 
express higher levels of NS cell markers: NG2, SOX2 and Nestin, while BMP-4 treatment leads to higher 
expression of GFAP, which is a marker of astrocytes; Scale bars, 100µm; (B, C) Less than 0.5% of cells treated 
with BMP-4 and FGF-2 are double-positive for GFAP and GFP (PDGFRα) potentially marking type B cells in 
vitro; Scale bar, 25 µm; 
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3.2.2 The GFP reporter is activated in PG1 cells in OPCs 
The kinetics of activation of the GFP reporter was next analysed each day over the course of 
a week using PG1-1 cultures (Figure 9A). Using flow cytometry I found that GFP-positive 
cells are present at <1% in the proliferating cultures. Following plating of cells in PDGF and 
FGF (removal of EGF) I observed emergence of 30-50% GFP-expressing cells between days 
3 and 6, with a drop at day 7 (Figure 9A). This drop in GFP may be related to the cell death 
and likely selection that occurs following removal of growth factors (PDGF and FGF) on day 
4 and so increases may be explained by selection. However, through days 1-4 there is little 
cell death. Western immunoblotting and immunofluorescence microscopy, confirmed 
expression of GFP reporter at day 4 of differentiation (Figure 9B and D). GFP expressing 
cells were noted to have the characteristic bipolar morphology of OPCs, and contrasted with 
nearby flat, spread morphology of GFP-negative cells – likely astrocyte cells (Figure 9C).  
The differences between cell lines in the efficiency of PDGFRα activation seem stable as 
PG1-3 typically gave lower GFP induction (Figure 9E). Variability between different clonal 
NS cell lines in efficiency and consistency of differentiations was noted previously in a wide 
range of different NS cell lines.  The explanation for this remains unclear.  
To confirm the OPC identity of GFP expressing cells, I next harvested GFP-expressing cells 
at day 4 of differentiation using fluorescence activated cell sorting (FACS) (Figure 10A). 
mRNA was harvested and qRT-PCR analysis performed to assess expression of PDGFRα as 
well as a series of differentiation markers in GFP-positive and -negative populations. 
PDGFRα and GFP mRNAs were enriched in the GFP-positive sorted fraction. Encouragingly 
further markers of OPCs were highly enriched in the GFP subpopulation, namely:   OLIG2, 
NKX2.2 and SOX10 (Figure 10B).   
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Figure 9. PG1 NS cells can differentiate into PDGFRα-positive oligodendrocyte progenitor cells in vitro. (A) Time-course 
flow cytometry analysis of GFP expression shows that PDGFRα-positive cells emerge on day 3-4 of differentiation with a 
peak of expression on day 6; analysis performed as a single technical experiment on PG1 and two clonal lines (PG1-1 and -
3), COR3-4 was used as a GFP-negative NS cell line (B,C) Images showing GFP activation during oligodendroglial 
differentiation (EGF withdrawal); Scale bars,  50µm (C) Oligodendrocyte progenitor cell (black arrow) has a characteristic 
bipolar morphology; Scale bar, 25µm; (D) Western blotting analysis showing expression of PDGFRα and GFP on day 4 of 
differentiation; (E) Flow cytometry analysis on day 4 of differentiation shows a variable expression of GFP between parental 
PG1 and two clonal lines (PG1-1 and PG1-3); the difference between PG1 and PG1-1, and PG1 and PG1-3 was statistically 
significant at p<0.05 (independent t-test; plotted mean ±SD; 2 biological replicates for each line); 
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When differentiated further, cells started expressing O4, a marker of oligodendrocyte lineage, 
on day 7 of differentiation and all O4 expressing cells were GFP-positive. However, not all 
GFP-positive cells were O4-positive, suggesting some limiting factor/signal in promotion of 
oligodendrocyte differentiation in our cultures (Figure 10C). Immunocytochemistry for 
OLIG2 and SOX10 confirmed that all OPCs and O4 cells co-expressed these two key 
regulators (Figure 10C and D). 
In summary, these data suggest that: 1) the PG1-1 and PG1-3 clonal NS cell lines express 
characteristic NS cell markers and are karyotypically normal. 2) GFP reporter is not 
expressed in undifferentiated NS cells but is activated following induction of differentiation. 
3)  GFP expressing cells are enriched in a range of OPC markers and display OPC 
morphology. 4) A subset of GFP-expressing OPCs can differentiate into O4-positive cells 
and express markers of oligodendrocyte lineage. Thus, PG1-1 and PG1-3 represent a useful 
cellular model for studies of PDGFRα activation during NS cell differentiation.  
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Figure 10. GFP-positive PG1-1 cell are enriched in markers of oligodendrocyte lineage.  (A) Typical plot of 
flow cytometry and gating strategy for the isolation of GFP-positive and GFP-negative cells used in qPCR 
analysis; (B) qPCR analysis reveals an enrichment of  oligodendrocyte lineage markers (including PDGFRα and 
SOX10) in GFP-positive cells; (C) GFP-positive OPCs are able to differentiate into O4-positive cells; Scale 
bars, 50µm; (D,E) Only a subset of cells positive for OLIG2, GFP and SOX10 become O4-positive; Scale bars, 
20µm (D), 75µm (E); 
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3.2.3 Acquisition of PDGFRα does not indicate commitment to differentiation 
The PG1 cells provide a useful tool to investigate the process of differentiation commitment. 
I therefore investigated whether acquisition of GFP/PDGFRα expression indicated a loss of 
responsiveness to EGF. NS cells were differentiated for 4 days (described in Methodology) 
and GFP-negative and GFP-positive cell populations were sorted. These isolated 
subpopulations were re-plated with either EGF and FGF-2 (self-renewal) or PDGF and  
FGF-2 (differentiation) for 4 days (Figure 11A). I found that GFP-positive cells were able to 
proliferate in response to re-exposure to EGF and extinguished expression of GFP after 4 
days. Cells plated in PDGF and FGF-2 could not be expanded continuously and rapidly 
exited cell cycle (Figure 11B). Interestingly, GFP-negative cells can activate the reporter after 
4 days in proliferating condition, followed by the differentiation period, at a level similar to 
the original GFP-positive population, suggesting that GFP negative cells are not committed to 
an alternative fate, but can also revert to the NS cell state (Figure 11B). 
My results indicate that activation of the GFP-positive state is reversible as cells can readily 
extinguish expression of the reporter and re-enter the cell cycle when reexposed to EGF  and 
FGF-2.  
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Figure 11. GFP-positive OPCs can be reverted to NS cell state. (A) Experimental design to establish the 
reversibility potential of the PDGFRα-positive state; (B) Microphotographs of sorted GFP-/+ cells incubated in 
proliferating or differentiating conditions to evaluate reversibility potential of OPCs show that PDGFRα 
expression is reversible with the EGF treatment and GFP status does not mean cell commitment to 
oligodendrocyte lineage; Scale bars, 150 µm; 
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3.2.4 Cell-cell contact affects activation of PDGFRα 
In addition to line-to-line variation in the proportion of GFP activation, it is also a feature of 
NS cell differentiation that there is variability between experiments in the differentiation 
efficiency. One potential explanation for this is the effect of cells’ density. To explore this 
further and to establish the optimal plating density for future chemical screens based on PG1 
cells I tested different plating densities and assessed GFP activation. 
Cells were counted and plated in identical numbers, but in variable vessels sizes, leading to a 
range of distinct densities (ranging from a 24-well plate to a T-25 flask) (Table 2). I scaled 
the volume of media in each vessel to ensure any secreted signals would be diluted to a 
similar final concentration. Thus, the cell density was the only variable between each 
condition.  
Table 2. Experimental setup for assessing the effect of cell density of PDGFRα activation 
 24-well plate 12-well plate 6-well plate T-25 flask 
Surface area 
(cm
2
) 
2 3.8 9.4 25 
Cells/cm
2 100,000 52,600 21,300 8,000 
 
Cells were incubated in differentiating conditions for 4 days and flow cytometry analysis was 
performed (Figure 12A). It was possible to observe a direct correlation between the plating 
density and the percentage of GFP-positive cells, with higher density increasing GFP 
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activation. A similar trend was observed in all three cell lines with GFP expression doubling 
from the lowest (8,000/cm
2
) to the highest (100,000/cm
2
) plating density (Figure 12B&C). 
This suggests that activation of PDGFRα is dependent on appropriate cell-cell signaling.  
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Figure 12. Cell-to-cell contact increases the activation of PDGFRα. (A) Flow cytometry plots from analysis 
performed on PG1-3 on day 4 differentiation show higher levels of GFP expression associated with smaller 
vessel (higher cell plating densities). (B) Results of flow cytometry analysis from three cell line show a similar 
trend regardless of the cell line used; Higher plating density translates into higher expression of PDGFRα 
(GFP); Analysis performed as a single technical experiment on three independent cell lines; (C) Correlation 
between density and GFP expression can be established as a similar trend was observed in all three cell lines 
tested (R
2
 analysis performed);  
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3.2.5 Establishment of mouse brain explants cultures 
We next assessed whether the PG1 cells could engraft and begin differentiation when placed 
into a brain slice culture. Explant cultures have a potential to reduce the need for animal 
testing and to bridge the gap between in vitro and in vivo studies. They can more accurately 
mimic the natural differentiation environment of neural cells, allowing for cell-to-cell contact 
interactions and signalling. They can also reduce the time needed to validate small molecule 
treatments as brain explants cultures infiltrated by cancer cells can be established in a matter 
of hours, requiring only enough time for attachment and infiltration of the explant layer by 
cancer cells. 
I therefore aimed to establish in the Pollard laboratory CNS slice cultures as a useful ex vivo 
tool to explore PG1 cell differentiation. ~100 um slices were generated using a vibratome and 
placed onto a cell culture insert. Interestingly, I observed high expression levels of Nestin in 
slices containing ventricles, marking the niche of neural stem cells (Figure 13A). I generated 
PG1 cells expressing constitutively the dsRed reporter under the control of a CAG-expression 
plasmid.  PG1-dsRED cells were able to engraft into the brain slices and survive long term in 
this artificial environment (Figure 13B). When treated with PDGF and FGF-2, the PG1 cells 
were able to differentiate into OPCs and express GFP reporter (Figure 13C). G144, a human 
GBM cell line, was used to test the potential for GBM studies using this model. Again, I was 
able to observe the infiltration of the explant layer for up to one week (Figure 13D). These 
data confirm that GFP reporter expression can be observed in cells plated into brain slices. 
However, we did not pursue further differentiation of cells or study their ability to generate 
mature oligodendrocytes. 
 
Chapter 3  Results 
93 
 
 
3.3 Discussion 
PG1 mouse NS cell lines express typical markers of neural stem cells and they are responsive 
to growth factors known to influence proliferation (EGF/FGF) or astrocyte differentiation. 
The normal karyotype for the mouse genome was observed in NS cells (n=40) and the 
generation of clonal and karyotypically normal NS cell lines was important, as these cell lines  
are later used in chemical screening experiments (Chapter 4). 
Figure 13. Mouse brain explant culture as a tool for oligodendrocyte differentiation studies. (A) Brain explant 
culture containing layers of cells from SVZ shows expression of Nestin marking SVZ stem cells with nuclei in 
blue (DAPI staining); (B) PG1 cells infiltrate the explant culture and (C) can differentiate into OPCs when EGF 
is withdrawn; Scale bars, 75µm; GFP expression marked with black arrows); (D) Human GBM cell line G144 
tested also infiltrates the explant culture; Scale bar, 20µm; 
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The generation of GFAP-positive GFP-positive type B cells was not observed in the GFAP 
cells  indicating these are unlikely to be quiescent astrocyte stem cells (Jackson, Garcia-
Verdugo et al. 2006) consistent with the downregulation of Sox2. I tested combinations of 
BMP-4 with other key regulators of NS behaviour, EGF, FGF-2 and PDGF.  Only when 
BMP-4 was delivered with FGF-2 did we observe any indication of GFAP and GFP co-
expressing cells. This is potentially interesting to pursue in future studies, as recent reports 
have suggested BMP and FGF treated NS cell lines may indeed have type B – quiescent stem 
cell characteristics (Martynoga, Mateo et al. 2013). In vitro expansion of these early, 
undifferentiated cells would be of interest to further delineate neural processes and to 
understand processes leading to their activation.  
Oligodendrocyte differentiation using PDGF and FGF-2 remains suboptimal, leading to only 
15-20% induction of OPCs in culture.  We found no effects of included Forskolin in the 
differentiation protocol (not shown) (Raible and McMorris 1990, Joubert, Foucault et al. 
2010). Chemical screening could therefore be valuable in order to identify molecules and 
pathways that increase the efficiency of this process. 
Not all PDGFRα-positive cells become O4-positive in vitro, which marks a possibility for 
other processes and factors being involved, but also defining different stages of 
differentiation. In a study by Ellison and de Vellis they recognised three different populations 
of cells expressing PDGFRα: GD3-positive, GD3-/O4-positive and O4-positive, which 
marked progenitor and preoligodendrocyte cells in development (Ellison and de Vellis 1994). 
As oligodendrocytes mature they lose expression of PDGFRα and NG2 and start expressing 
O4 antigen (Nishiyama, Komitova et al. 2009). This could mean that NS cells in my culture 
are a heterogeneous non-synchronised population at different stage of development.  
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We find that activation of PDGFRα expression does not mean that cells are committed 
towards oligodendrocyte lineage, as GFP-positive OPCs rapidly lost GFP expression when 
re-plated with the EGF and FGF-2 present in the media. Moreover, they were able to 
proliferate and presented a characteristic NS cell morphology. The fact that sorted GFP-
negative cells were able to activate GFP when replated with PDGF and FGF-2 in the media 
suggests that this process could be dependent on some intrinsically determined mechanism 
(such as transcription factor heterogeneity), with 15% GFP-positive cells at any given time 
following induction of differentiation. Further analysis is required to validate this finding.  
Cell-to-cell contact plays an important role in the activation of PDGFRα. I observed a direct 
correlation between the cell plating density and the percentage of GFP-positive cells, which 
suggests possible involvement of both autocrine and paracrine signalling. Plating density is 
important for the survival of OPCs when cultured on their own, either as a result of 
shakedown of a flask and replating or by FACS. High-density cultures yield the highest 
percentage of O4-positive oligodendrocytes, while low-density cultures remain at the NG2-
positive progenitor stage (Yang, Watanabe et al. 2005). The high-density is associated with 
increased levels of a cell cycle inhibitor p27(Kip1), reduced expression of cyclin A and 
changes in phosphorylation levels of Rb. Interestingly, these changes are reversible, when 
cells are replated at a lower density (Nakatsuji and Miller 2001). This observation could 
somehow explain the lack of commitment of sorted PDGFRα-positive cells, as possibly they 
were not plated at a high enough density.  
Brain slice culture more closely mimics the in vivo environment than in vitro differentiation 
protocols. There are two challenges identified in the explant culture. Firstly, only a small 
proportion of cells actually infiltrates the explants layers. Secondly, it can be difficult to find 
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a focal plane to image and track the infiltrative cells as they are positioned between layers of 
other explants cells. Brain slice culture is therefore of value in determining the maturation 
and function of cell populations, but is less suitable for higher throughput studies such as 
chemical screen and mechanistic studies.  
3.4 Summary 
In summary, these results confirm that I have generated a novel and useful cell lines for 
studies of the transition from neural stem cell/radial glia to an oligodendrocyte specified 
progenitor. These cell lines are ideally suited for chemical and genetic screening.  
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Chapter 4 Chemical screening for modulators of NS cell differentiation  
4.1 Introduction 
High content screening (HCS) refers to the phenotypic screening of cells in a manner in 
which extensive molecular and morphological information is extracted from responses of 
cells to experimental treatments (either chemicals or genetic perturbations). Chemical screens 
might include small pharmacologically active molecules, peptides, or antibodies. Genetic 
screen encompass RNA molecules leading to inhibition of gene expression, a process known 
as RNA interference (RNAi) (Taylor, Haskins et al. 2007, Haney 2008) and more recently the 
use of synthetic nucleases such as the CRISPR/Cas system (Shalem, Sanjana et al. 2014, 
Wang, Wei et al. 2014). 
Chemical genetics has been used extensively over the past two decades as a method for 
identifying potentially interesting compounds and signalling pathways using small molecule 
libraries (Schreiber 1998, Crews and Splittgerber 1999). To cause a specific phenotypic 
change, a small molecule has to be able to cross the cell membrane or target cell surface 
molecules and must display some specificity in its activity (Eggert and Mitchison 2006).  
Using HCS it is possible to define in an unbiased manner those pathways which control 
specific biological processes, and this ultimately provides the foundation for developing new 
drugs that can be used in medicine. Two strategies can be employed, either screening of 
compound libraries with known biological targets, or screening of new chemical entities 
generated through chemical synthesis. The latter is more typically used in the pharmaceutical 
industries and uses more high throughput, as many compounds will have poor drug-like 
qualities such as cell permeability.  Target identification is considered to be  the rate limiting 
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step in chemical genetics/high-content screening (Eggert and Mitchison 2006). Small 
molecules with known targets therefore can overcome this bottleneck in defining what the 
specific molecular target and pathway that has affected the cells.  
HCS is considered a discovery tool in stem cell biology, where the goal is to uncover specific 
effects on cell fate, e.g. differentiation, death, proliferation, senescence and where cellular 
heterogeneity in the differentiating cell population is commonplace. HCS allows scientists to 
track non-uniform and asynchronous differentiation of stem cells in vitro over time and to 
monitor the behaviour of transient intermediate progenitor cells, a clear advantage over 
endpoint assays (Danovi, Folarin et al. 2012). HCS is also implemented in studies of cancer-
derived stem cells. Small molecules with potent biological effects on the fate of these cells 
represent useful research tools and new drug leads for regenerative medicine and oncology 
(Danovi, Folarin et al. 2012).  
Small molecules that can modulate the lineage choice and differentiation of NS cells may 
have value as research tools, for use in regenerative medicine or for use in new types of 
differentiation therapy for brain cancer. To search for small molecules capable of modulating 
differentiation of NS cells and to dissect pathways modulating this process, I set up a 
chemical screening of commercially available known small molecule inhibitors of ‘classic’ 
stem cell and developmental pathways, as well as known kinase inhibitors. A total of 463 
compounds from three distinct libraries of commercially available small molecules were used 
(‘StemSelect’, ‘InhibitorSelect I’ and ‘InhibitorSelect II’; obtained from EMD Calbiochem 
Merck Millipore. The StemSelect library consisted of 303 pharmacologically active small 
molecules previously implicated in regulation of development and stem cell pathways. The 
InhibitorSelect libraries consisted of 160 kinase inhibitors giving a total of 463 screened 
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molecules.  Our choice of high content screening platform was the Incucyte FLR device, 
which enable image acquisition of phase images (10x) and GFP fluorescence in live cells in 
an automated manner directly in the tissue culture incubator. 6 x 96 well plates can be 
screened with this device, and this is compatible throughput for the small libraries we were 
screening. 
4.2 Results 
4.2.1 Optimisation of Incucyte FLR live cell screening conditions 
Our goal was to search for compounds that could influence (increase or decrease) the 
numbers of OPCs (GFP-positive) that emerge following differentiation of NS cells. A pre-
requisite of any cell based screening assay is the optimisation of culture conditions and 
parameters for the differentiation and assessment of the sensitivity of the assay. Initial studies 
of GFP activation showed that complete medium in which NS cells are grown has high 
autofluorescence levels, which are detrimental in an imaging-based screening, increasing 
background and reducing the signal to noise. To solve this problem I compared our standard 
complete NS cell media (DMEM-based) with that using EMEM. EMEM contains lower 
levels of vitamin B12 (Riboflavin), which is responsible to the autofluorescence in the 488nm 
region. Exchange of DMEM with EMEM did not affect cell viability or differentiation 
potential, but we indeed found a much better signal in the GFP expressing OPCs in this 
condition (Figure 14A).  
Another important factor was to assess if the amount of medium used could be reduced 
without compromising the consistency of differentiation. I found that cells struggled to 
survive with lower volumes for the required time of 3-4 days and increased non-specific 
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death was seen at day 2. This was possible due to reduced concentrations of growth factors 
and other molecules, which were at that point used up by cells in culture (Figure 14B). As the 
chemical screening experiment was planned to last for an uninterrupted period of 3 days I had 
to find the media volume which would not affect cell survival and at the same time allowed 
for a correct drug concentration in every well. I observed that 50uL of media in a well of a 
96-well plate was the minimum volume to satisfy both requirements when 6x10
3
 PG1-1 
cells/well were used (data not shown). 
I also tested a range of different cell culture plastics/substrates (no coating versus, gelatin or 
laminin). Only laminin coating enabling sufficient cell attachment to the bottom of the vessel. 
The test of three different concentrations of laminin showed that only the standard 
concentration (described in Methodology) provided fully attached cells, with no sign of cell 
clumping, which was important for the chemical screening as I was able to easily distinguish 
individual cells, improving accuracy of automated CellProfiler analysis of the chemical 
screening (Figure 14C).  Ibidi supply tissue culture plastics that is optimised for high 
resolution imaging studies and we tested these plasticware. Although image quality was 
slightly increased we found significant clumping/detachment with this plasticware.  
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Mouse NS cells were deposited into 96-well plates under differentiation conditions (see 
Methodology) and compounds were added while cells were still in suspension using the Cybi 
Selma 96-head liquid handling device (CyBio). Plates were then transferred to a live-cell 
imaging device (Incucyte, Essen BioSciences) and each well was imaged over the course of 
66 hours at 3 hours intervals. More frequent imaging to achieve a finer time-course of 
differentiation was explored, however there was significant non-specific cell death due to 
phototoxicity at 1 and 2 hour intervals (not shown). Data were then processed and analysed 
using CellProfiler and R 2.11 software, with dedicated analysis pipelines established 
similarly to previous screens from our laboratory (Danovi, Folarin et al. 2012) (Figure 15). 
Figure 14. Optimisation of Incucyte FLR live cell screening conditions. (A) Reduction in media 
autofluorescence was achieved by switching the basal media from DMEM to EMEM; (B) Media volume affects 
cell survival over time, with higher volumes promoting an overall increase in cell survival; (C) Reduction in 
laminin concentration causes cell clumping, which can affect analysis of High Content Screening data;  
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Figure 15. Chemical screening process pipeline.  Cells are isolated from the mouse foetal forebrain and NS cells 
are culture as primary stem cell lines in vitro. Compounds and cells are added to 96-well plates using a semi-
automated liquid handling device (CYBI-SELMA). Live cell imaging system, Incucyte, is used to take images 
of each well of a 96 well plate at the established intervals. CellProfiler software is then used for image 
processing and analysis, followed by data storage and creation of tables for analysis using CellProfile-R, 
MySQL and R(CRAN). 
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4.2.2 Screening of StemSelect Library for small molecules that modulate OPC lineage 
commitment 
To find modulators of NS cell differentiation I firstly set out to screen the StemSelect 
Library. This library contains 303 selected small molecules known from previous literature to 
influence stem cell pathways. I screened this library using PG1-1 cell line in four independent 
chemical screenings performed over a period of six months. The results were normalised to 
account for differences between experiments. Criteria for selection for further study were 
either complete inhibition of GFP expression or any increase in GFP expression as observed 
using generated heat maps. As it is common in a chemical screening to identify ‘false’ 
positive compounds we decided to use flow cytometry as a method to accurately evaluate the 
potential of molecules which met our criteria of GFP inhibition or increase in activity.  
No compounds within this library were able to increase the frequency of GFP cells compared 
to control wells with 18 false-positive compounds observed (data not shown). However, 12 
compounds that could suppress GFP expression without effects on general cell viability were 
identified (Table 3). These molecules were further validated using flow cytometry. Most 
notably, compounds classified as Histone Deacetylase Inhibitors (HDACi) appeared to be the 
most effective GFP blockers, as 5 (Apicidin, HDACi III, HDACi VI, Scriptaid and HDACi 
IV) out of 12 selected molecules belong to this protein family. Figure 16 presents results of 
the high content screening analysis, which was composed of investigation of generated heat 
maps showing absolute and relative change in GFP expression.  
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Table 3. Summary of GFP inhibitors identified in the chemical screening. Twelve compounds were identified as 
potential GFP inhibitors, which required further validation; Relative mean change in GFP expression was 
compared to DMSO controls at the last experimental time-point (66 hours);  
GFP inhibitor 
Relative mean change 
 in GFP expression 
Standard deviation 
Apicidin 0.08 0.08 
Corticosterone 0.53 0.08 
Dexamethasone 0.58 0.27 
ACA 0.65 0.18 
HDACi III 0.2 0.18 
HDACi IV 0.51 0.1 
HDACi VI 0.41 0.16 
Nemadipine-A 0.41 0.14 
Scriptaid 0.4 0.1 
Nigericin 0.2 0.14 
Valproic acid 0.64 0.25 
Withaferin A 0.31 0.07 
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Figure 16. Representation of chemical screening results in a form of heat maps. (A) Absolute change in GFP 
expression over time in all drug-treated wells of 96-well plates; (B) The same data as A presented as relative 
change in GFP expression, compared to average GFP expression in control wells at each time-point with 
Nigericin showing reduction in GFP expression (marked with yellow colour) on day 3 of differentiation; Both 
heat maps show combined results from 4 independent screenings as described in Methodology; (C) Results of 
the 4 most effective GFP inhibitors identified in the screening shown as a relative change in GFP expression 
compared to control wells (all graphs);  
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To validate the identified hits from the initial screen flow cytometry analysis was used in an 
independent experiment with the same compounds. This confirmed the activity of the family 
of Histone Deacetylase Inhibitors (HDACi) in blocking activation of the PDGFRα reporter 
(Figure 17A). The four most potent inhibitors identified were: Apicidin, Histone Deacetylase 
Inhibitor III (both HDACi), Withaferin (NFkB Activation Inhibitor) and Nigericin  
(a polyether antibiotic and ionophore) were then used for the further analysis as they 
appeared effective in a complete inhibition of GFP expression. I validated these four 
molecules using independent experiments and quantitation of GFP using flow cytometry 
allowed for a more precise analysis of GFP expression. A lack of GFP expression due to the 
small molecule treatment suggested that cells were blocked from becoming oligodendrocyte 
progenitor cells. (Figure 17B). Morphology of the treated cells also suggested that the 
characteristic bipolar morphology of oligodendrocyte progenitor cells did not emerge in the 
presence of each of these compounds (Figure 17C).  
 
 
 
 
Chapter 4  Results 
107 
 
 
 
 
 
 
Figure 17. Four molecules were selected as GFP inhibitors for post-screening analysis.   (A) Results of a flow 
cytometry validation of small molecules identified in the chemical screening as GFP inhibitors; HDACi are 
marked with *; Validation performed as a single experiment on two clonal cell lines; (B) The four most 
effective GFP inhibitors can completely block GFP activation – but without any effect on cell viability; (C) Live 
phase-contrast images showing a change in morphology in drug-treated cells; Scale bars, 40µm; 
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4.2.3 Screening of InhibitorSelect Libraries for molecules that modulate OPC lineage 
As no compounds that stimulated OPC specification were identified, we next assessed the 
phenotypic consequences of another small compound library called InhibitorSelect library 
which comprises 160 known kinase inhibitors. Cells were plated in 96-well plates and 
compounds were added while cells were still in suspension (as outlined in Methodology). As 
this was an additional chemical screening to the screening of the StemSelect library, it was 
performed as a single experiment with three technical replicates.  
I was not able to identify any compounds that could induce increased numbers of GFP-
positive cells based on the analysis of images generated during the screening. However,  
9 GFP inhibitors were observed (K-252a, NFkBi, Staurosporine, IC261, SB 203580, Akt 
Inhibitor IV, Fascaplysin, CDK4 Inhibitor III, SU9516).  
The validation was performed at three different concentrations of kinase inhibitors: 10 nM, 
100 nM and 1 uM (Figure 18A). Most notably, two compounds: K-252a (Staurosporine 
analog) and NFkB Activation Inhibitor (known as 545380-34-5), appeared to block GFP 
expression at a level similar to previously identified ‘hits’ from StemSelect screening (Figure 
18B).  
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Figure 18. Validation of GFP inhibitors identified in the screening of the InhibitorSelect library. (A) Flow 
cytometry validation of compounds identified as GFP inhibitors (cytotoxic drug concentrations not shown) (B) 
Flow cytometry graphs and live phase-contrast microphotographs of the two most effective GFP inhibitors:  
K-252a and NFkBi; 
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4.2.4 Chemical screening for agents that drive OPC differentiation to O4-positive 
oligodendrocytes 
As my original chemical screening did not identify compounds that could enhance OPC 
specification I next pursued a modified screening strategy in which we searched for agents 
that might act on the 20% of OPC-GFP positive cells and drive their 
differentiation/maturation into oligodendrocytes expressing O4. For this we used the same set 
of chemical libraries and assessed them by visual inspection looking for cells displaying 
characteristic oligodendrocyte morphology (Figure 19A).  
Quabain and gamma-Secretase Inhibitor IX were identified using these assays as compounds 
that resulted in increased proportion of O4 cells (described in Methodology). Quabain 
appeared to effectively improve cell survival, showing a reduced number of apoptotic cells, 
when compared to DMSO control. Gamma-Secretase Inhibitor IX most likely acted as a 
selective inhibitor of GFP-negative cells, leaving the majority of GFP-positive cells in culture 
(Figure 19B). The hits from this screen were not pursued further as there was no compound 
identified that increased the absolute numbers of GFP cells.  
 
 
 
 
 
Chapter 4  Results 
111 
 
 
Figure 19. Chemical screening of StemSelect and InhibitorSelect compound libraries to uncover molecules 
promoting formation of O4-positive cells. (A) A schematic of the O4 screening experimental design. NS cells 
were allowed to differentiate into GFP-positive OPCs, at which point drugs were added. After an additional four 
days of differentiation cells were fixed and analysed using light microscopy; (B) Microphotographs of 4% PFA-
fixed cells showing compounds of interest, selected on the basis of improved cell survival (Quabain) and 
selection of  GFP-positive cells (gamma-Secretase Inhibitor IX); GFP expression showed in the green channel; 
Scale bars, 40µm; 
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4.3 Discussion 
Mouse NS cell lines are a valuable cellular model for studies of transcriptional and signalling 
pathways that influence stem cell self-renewal, lineage commitment and differentiation. We 
reasoned that a HCS approach with mouse NS PDGFRα-GFP reporter cell lines might allow 
us to identify compounds and associated pathways that would improve the differentiation 
process in vitro and might have value in the treatment of human brain cancer, or for directed 
differentiation of human stem cells for use in regenerative medicine. 
These experiments have demonstrated the value of adherent culture in enabling identification 
of compounds that can modulate neural stem cell fate – with many members of the HDAC 
inhibitors blocking oligodendrocyte lineage specification. Such a screen would be more 
challenging if culturing the stem cells using the more widely used ‘neurosphere’ culture 
regime.  
Autofluorescence can cause a problem in reporter-based assays and in HCS in particular, as it 
is crucial for the software to recognise background from the fluorescent reporter protein. 
Understanding of the limitations and specifications of devices used can be helpful, as the 
contrast can be improved by using reporter with the emission different than the source of 
autofluorescence, but this is possible only if the device can analyse the given light spectrum. 
Riboflavin was identified in a number of studies as a key factor interfering with GFP imaging 
analysis (Surribas, Resina et al. 2007, Bogdanov, Bogdanova et al. 2009). Creation of media 
composition with reduced riboflavin concentration can address this issue.  
One of the drawbacks of the NS cell culture in vitro as a monolayer is the use of laminin or 
collagen as agents promoting adherence of cells to the vessel surface. These molecules could 
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potentially alter the expression of cell surface receptors responsible for adhesion, migration, 
proliferation and differentiation (Ariza, McHugh et al. 2010, Jurga, Dainiak et al. 2011). 
Interestingly, use of hydrogel-based 3D-scaffold with laminin, showed enhanced neuronal 
differentiation and survival rate, when compared to 2D-cultures (Ortinau, Schmich et al. 
2010). Although laminin has its limitation, it still outweighs the use of neurosphere culture in 
the HCS setting.  
The four selected compounds from the StemSelect library were identified in four independent 
chemical screening experiments, which shows that the chemical screening can offer 
reproducible results. Moreover, compounds classified as HDACi clustered together despite 
being part of different 96-well plates, showing the importance of their activity in 
oligodendrocyte differentiation. This finding is discussed further in the General Discussion. .  
A chemical screening of the InhibitorSelect library identified another molecule, which was 
able to inhibit GFP expression at a level similar to NFkBi, called K-252a. It was not further 
analysed as it is a Staurosporine analog. Staurosporine is an alkaloid isolated from bacterium 
Streptomyces staurosporeus. It is a potent, but not specific inhibitor of protein kinases 
(Karaman, Herrgard et al. 2008), commonly used to induce apoptosis, thus it is not surprising 
that it did not lead to oligodendrocyte differentiation.  
Quabain and gamma-Secretase Inhibitor IX were the two compounds identified in the 
chemical screening for agents that drive OPC differentiation into O4-positive 
oligodendrocytes. Quabain improved cell survival, showing reduced number of apoptotic 
cells, when compared to DMSO control. Gamma-Secretase Inhibitor IX acted as a selective 
inhibitor of GFP-negative cells, leaving the majority of GFP-positive cells in culture. 
Quabain, also known as ouabain or g-strophanthin is a cardiac glycoside. It binds to and 
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inhibits activity of the plasma membrane Na
+
/K
+
-ATPase. It also indirectly affects handling 
of calcium ions by sodium calcium exchanger (NCX). Quabain, at nanomolar or lower 
concentrations can stimulate the Na
+
/K
+
-ATPase (Gao, Wymore et al. 2002). As the chemical 
screening was performed at 1uM concentration it would suggest that quabain acted as an 
inhibitor of Na
+
/K
+
-ATPase. Interestingly, similar to my findings quabain was shown to 
increase survival of retinal ganglion cells in vitro, though at the significantly lower 
concentration of 3nM. This was associated with activity of protein kinase C, which when 
inhibited blocked the effect of quabain (de Rezende Correa, Araujo dos Santos et al. 2005).  
Gamma-Secretase is a key regulator of myelination. Gamma-Secretase inhibitors enhance 
differentiation and ensheathment of oligodendrocytes. Differentiation of OPCs is inhibited by 
Notch1 signaling (Wang, Sdrulla et al. 1998). Treatment of OPC cultures with DAPT, a 
Gamma-Secretase inhibitor, increases number of MBP-positive cells. It is then possible that 
Gamma-Secretase Inhibitor IX identified in the chemical screening acts by inhibition of 
Notch signalling and promotes differentiation of OPCs at the cost of other GFP-negative 
cells, which do not survive in the absence of growth factors. Although these compounds were 
not explored further in this study, in future it would be worth exploring whether combinations 
of Quabain and Gamma-Secretase might identify an improved protocol for OPC generation 
from NS cells or pluripotent stem cells. Further studies would be needed to establish the role 
of the identified small molecules and their impact on cell proliferation, differentiation ability 
and survival.  
4.4 Summary 
We have demonstrated the utility of PG1-1 cells for live cell image-based chemical 
screening. Conditions for screening were optimised and 463 different known 
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pharmacologically active compounds were assessed for their ability to influence OPC lineage 
specification.  Five molecules effective at blocking activation of PDGFRα: two HDACi 
(Apicidin, HDACi III), two NFkB inhibitors (Withaferin, NFkBi) and a polyether antibiotic 
and ionophore (Nigericin) were identified. Chemical screening for agents that drive OPC 
differentiation to O4-positive oligodendrocytes identified two molecules which could be 
investigated further, quabain (increased cell survival) and gamma-Secretase Inhibitor IX 
(selective survival of OPCs). No compounds were identified that promoted OPC 
specification.   
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Chapter 5 Characterisation of the cellular responses of newly identified 
small molecule modulators of NS cell differentiation 
5.1 Introduction 
Compounds identified following the screening of the StemSelect and InhibitorSelect 
chemical libraries targeted a range of different biochemical pathways/processes. Apicidin and 
HDACi III act as histone deacetylase inhibitors. Withaferin and NFkBi block NFkB pathway 
(Withaferin has also been shown to disrupt intermediate filaments such as Vimentin), while 
Nigericin is an ionophore and a polyether antibiotic.  
I investigated the role of molecular pathways affected by the identified small molecules, with 
the focus on neural development, cell and cancer biology. This allowed me to further 
understand what happens to mouse neural stem cells at different stages of neural 
differentiation, but also to put it into perspective for GBM differentiation studies.  
5.1.1 HDAC signalling 
HDACi, block histone deacetylation, and together with histone acetyl transferases (HATs) 
alter the packaging of DNA into chromatin. The reversible modification of core histones’ 
terminal process is a major epigenetic mechanism used to regulate gene transcription in 
eukaryotic cells. HATs acetylate lysine residues in core histones, which leads to a more open, 
transcriptionally active chromatin. HDACs remove the acetyl groups from the lysine 
residues, which results in a more condensed, and therefore less transcriptionally active 
chromatin. HDACi can block this process, locking histones into a permanently  
hyperacetylated and hence active state (Dokmanovic, Clarke et al. 2007). Several HDACi 
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have been shown to act as cytostatic agents inhibiting proliferation of tumour cells, triggering 
cell cycle arrest, apoptosis or differentiation. Currently there are 18 HDACi known to human. 
They are categorised into four classes, which are based on their homology of accessory 
domains to yeast HDACs.  
The process of histone acetylation and de-acetylation therefore indirectly affects non-histone 
proteins, including transcription factors by altering their ability to be turned on or off. The 
effect on activity can vary with enhanced activation or repression being a possibility. 
Moreover, acetylation can affect non-histone transcription factors in a direct manner as these 
molecules are known to be modified by acetylation (Yang and Seto 2007). A well known 
example of a non-histone protein that is regulated by acetylation is p53. Therefore 
interpretations of the phenotypic responses of cells to HDACi are not straightforward in 
terms of the specific underlying molecular pathway.  
A sequential activity of specific HDACs could be important for the differentiation of distinct 
populations of glia and neurons. Neural stem cells and progenitors have been shown to switch 
expression of HDAC1 and HDAC2 as they commit to a neurogenic lineage. Administration 
of the HDACi valproic acid (VPA) decreases the production and differentiation of cells in the 
dentate gyrus, rostral migratory stream and the olfactory bulb (Foti, Chou et al. 2013).  
Deletion of HDAC1 or HDAC2 in developing neurons results in severe hippocampal 
abnormalities and lethality by postnatal day 7 (Montgomery, Hsieh et al. 2009). Interestingly, 
another study showed that VPA induced neuronal differentiation of adult hippocampal neural 
progenitors and inhibited differentiation of astrocytes and oligodendrocytes. Hsieh et al. 
observed upregulation of neuron-specific genes, including NeuroD, a neurogenic basic helix-
loop-helix transcription factor (Hsieh, Nakashima et al. 2004).  
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5.1.2 NFkB signalling   
NFkB is a protein complex controlling transcription of DNA. It forms a cellular response to 
stimuli like stress, free radicals, bacterial and viral antigens, and cytokines (Gilmore 2006). 
There are five mammalian NFkB family members, which are divided into two classes. They 
share a structural homology with the retroviral oncoprotein v-Rel (Rel homology domain in 
the N-terminus) and hence they can be classified as NFkB/Rel proteins (Gilmore 2006). Class 
II NFkB, including RelA, RelB and c-Rel, have a transactivation domain in the C-termini. 
Class I molecules are synthesised as large precursors, called p105 and p100, which are then 
processed to form mature NFkB subunits, p50 and p52. This process is mediated by the 
ubiquitin/proteasome pathway, where ankyrin repeats of the C-terminal are selectively 
degraded (Karin and Ben-Neriah 2000). Moreover, class I molecules are considered to be 
transcriptional repressors as they have no intrinsic ability to activate transcription.  
NFkB belongs to the family of “rapid-acting” primary transcription factors, which are present 
in cells in an inactive state and become activated without a need for a new protein synthesis. 
The signalling pathway can be activated by a variety of stimuli, such as tumour necrosis 
factor α (TNFα), reactive oxygen species (ROS) and cocaine (Chandel, Trzyna et al. 2000).   
NFkB dimers in unstimulated cells are bound by Inhibitors of kB (IkBs), which contain 
multiple copies of ankyrin repeats. IkBs mask nuclear localisation signals (NLS) of NFkB 
and keep them inactive in the cytoplasm (Jacobs and Harrison 1998). Activation of a IkB 
kinase (IKK) leads to degradation of IkB proteins and release of the NFkB complex.  IKK is 
composed of a heterodimer of catalytic subunits IKKα and IKKβ with a regulatory protein 
called NFkB essential modulator (NEMO), also known as IKKγ.  
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IKK phosphorylates two serine residues in IkB regulatory domain, leading to their 
ubiquitination, followed by degradation in a proteasome. Once released, the NFkB complex 
is free to enter the nucleus and activate expression of genes, which can then trigger the 
physiological response. Moreover, the NFkB triggers expression of its own repressor, IkBα 
leading to reinhibition of NFkB and its inhibition in the cytoplasm (Nelson, Ihekwaba et al. 
2004).  
Activation of the NFkB/RelB:p52 dimer, described as a non-canonical pathway, can be 
initiated by some differentiating or developmental stimuli, including B-cell activating factor 
(BAFF), which leads to activation of signals needed for formation and maintenance of B cells 
or lymphotoxin B, which leads to activation of an inflammatory response. This pathway uses 
an IKK complex that comprises the two α subunits, but not NEMO. Ligand-induced 
activation of NFkB-inducing kinase (NIK) leads to phosphorylation and activation of IKKα 
complex by NIK. IKKα complex can then phosphorylate p100 leading to the processing and 
liberation of the p52/RelB heterodimer, which can actively regulate gene expression in the 
nucleus (Bonizzi, Bebien et al. 2004). In conclusion, the non-canonical pathway depends on 
NIK processing of p100 into p52, while the canonical pathway relies upon NEMO-IKK 
degradation of IkB molecules.  
Members of the NFkB family are expressed postnatally in the subventricular zone and in the 
rostral migratory stream. RelA and p50 are expressed in migrating neuron precursors, radial 
glial cells and a population belonging to the astrocytic lineage. RelB component of the 
pathway is expressed only in migrating neuron precursors (Denis-Donini, Caprini et al. 
2005). NFkB pathway is constitutively activated in glutamatergic neurons (Kaltschmidt and 
Kaltschmidt 2009). In Schwann cells NFkB is involved in the myelination process. It is 
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highly expressed in pre-Schwann cells and then progressively declines as cells differentiate 
(Nickols, Valentine et al. 2003).  
5.1.3 Ionophore signalling  
Ionophores are lipid-soluble molecules used to transport ions across the lipid bilayer of the 
cell membrane. There are two classes of ionophores, chemical compounds and channel 
formers. Chemical compounds bind to a particular ion and shield its charge from the 
surrounding environment and facilitate the crossing of the hydrophobic interior of the lipid 
membrane. Channel formers introduce a hydrophilic pore into the cell membrane and allow 
ions to pass through without the contact with the membrane’s hydrophobic interior.  
Antibiotic properties of ionophores come from the fact that they can disrupt the 
transmembrane ion concentration gradients, which are crucial for the survival and proper 
functioning of microorganisms. A number of ionophores were identified and described, 
including Gramicidin D, acting on H
+
, Na
+
 and K
+
, which was obtained from the soil 
bacterial species Bacillus brevis. This molecule is active against Gram-positive bacteria, 
except the Gram-positive bacilli and against select Gram-negative bacteria.  
Nigericin is derived from Streptomyces hygroscopicus and is structurally and functionally 
similar to another antibiotic known as monensin. Monensin is isolated from Streptomyces 
cinnamonensis. It preferentially forms complexes with monovalent cations like Li
+
, Na
+
 and 
K
+ 
and can transport them across lipid membrane in an electroneural (non-depolarizing) 
exchange
 
(Pinkerton and Steinrauf 1970). Sodium ions can be transported in both 
electrogenic and electroneural manner (Huczynski, Janczak et al. 2012). 
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 Nigericin acts as a H
+
, K
+
, Pb
2+
 ionophore, mostly as an antiporter of H
+
 and K
+
. It is active 
against the Gram-positive bacteria and inhibits the Golgi function in eukaryotic cells. Of 
great interest to my studies, Nigericin was identified in a high-throughput chemical screen as 
one of the molecules inhibiting growth of breast cancer stem cells (Gupta, Onder et al. 2009). 
It inhibits mammary tumour growth in vivo and induces increased epithelial differentiation of 
tumour cells. The ionophore is also effective in the treatment of nasopharyngeal carcinoma 
(NPC). A study using cell lines with high and low proportion of CSCs showed that Nigericin 
selectively targets CSCs and makes them sensitised to cisplatin, a widely used clinical drug 
(Deng, Liang et al. 2013). Nigericin was shown to effectively sensitize glioma cell lines to 
TRAIL-mediated apoptosis via ER stress, CHOP-mediated DR5 upregulation and c-FLIP 
downregulation (Yoon, Kang et al. 2013).  
In a study of chronic lymphocytic leukemic Nigericin was identified as a potent inhibitor of 
the Wnt signalling cascade (Lu, Choi et al. 2011). In Wnt overexpressing HEK293 cells, 
Nigericin blocked the phosphorylation of the lipoprotein receptor-related protein 6 (LRP6) 
and induced its degradation. Expression of Wnt target genes including LEF1, cyclin D1 and 
fibronectin was down-regulated, while normal human peripheral blood lymphocytes resisted 
the toxicity (Lu, Choi et al. 2011). Canonical Wnt signalling through beta-catenin pathway 
prevents oligodendrocyte differentiation from progenitor to an immature state. Using a Wnt 
antagonist Shimizu et al. observed an increase in the number of immature oligodendrocytes in 
the spinal cord explant culture (Shimizu, Kagawa et al. 2005).  
Chapter 5  Results 
122 
 
5.2 Results 
5.2.1 Investigation of drug concentrations 
The chemical screening was performed at only one drug concentration (1uM for StemSelect 
and 100nM for InhibitorSelect). I further tested a range of concentrations: 0.05uM-10uM for 
compounds identified from the StemSelect library and 1nM-1uM for the NFkBi.  
I used both live cell imaging and viable cell count to determine the effect of different drug 
concentrations on cell survival. The process of viable cell count was automated, to reduce 
potential user bias. Cells were counted using ViCell Cell Viability Analyzer (Beckman 
Coulter) (Figure 20A and B).  
Concentration >1uM led to cell death, <1uM did not affect the morphology and GFP 
inhibition to the same extent as the original screening concentration. Therefore, I used 1uM 
as a concentration used for validation of Apicidin, HDACi III, Nigericin and Withaferin. For 
NFkBi I picked two concentrations: 100nM and 1uM whenever possible. 
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Figure 20. Higher concentrations of small molecules affect viability of NS cells. (A) Compounds showed a 
cytotoxic effect on cell viability especially at doses >1uM; (B) Microphotographs showing live, drug-treated 
cells at the concentration used in the chemical screening; Scale bars, 40µm; 
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5.2.2 Is the emergence of GFP-positive OPCs ablated due to blockade of induction or 
selective killing of OPCs? 
As compounds identified in the chemical screening were effective at blocking activation of 
GFP reporter I tried to determine the explanation for loss of GFP. At least two possibilities 
could account for lack of GFP: induction of PDGFRα gene expression may fail to occur, or 
alternatively GFP reporter induction may occur, but cells are then rapidly be killed. To 
explore these two possibilities I first investigated whether GFP-positive cells are selectively 
killed by the inhibitors. It was possible to answer this question by firstly differentiating NS 
cells into GFP-positive OPCs, followed by addition of the compounds (Figure 21B). This 
contrasts the original chemical screening design, where NS cells triggered to differentiate in 
the presence of inhibitors (Figure 21A).  
After adding drugs at day 3 to cultures containing ~15% GFP cells, I observed that although 
there is a reduction in GFP numbers following exposure to inhibitors, there was not a 
complete ablation of GFP as observed when inhibitors were given at the onset of 
differentiation (Figure 22). Compounds belonging to the HDACi family did appear to reduce 
percentage of GFP-positive cells after 48 (day 6 total) and 72 hours (day 7 total) and 
therefore both a blockade in induction, and some sensitivity of GFP cells to the presence of 
HDACi may occur. NFkBi in both instances caused unspecific cell cytotoxicity and cell death 
and I was not able to validate its potential. Nigericin appeared to act similarly to NFkBi, 
causing cytotoxicity, with reduced percentage of GFP-positive cells (Figure 21C). The 
subject of drug cytotoxicity and possible explanations are discussed further in the Discussion 
part of this thesis.  
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Figure 21. Small molecules can selectively reduce the number of GFP-positive cells. (A) Chemical screening 
setting; Drugs were added to the NS cells at the induction of differentiation; (B) Experimental setting to address 
selective targetting of GFP-positive cells; Cells were allowed to differentiate into GFP-positive OPCs at which 
point drugs were added to estimate their potential in selective targeting of these cells; (C) Results of a flow 
cytometry analysis showing that Apicidin, HDACi III, and Nigericin selectively reduced the number of GFP-
positive cells when compared to a control (Differentiation Day 6; p<0.05; double-sided t-test);   
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5.2.3 Differentiation potential of GFP inhibitors 
Figure 22. Selective targeting of GFP-positive cells was not observed using live cell imaging. Nigericin and 
NFkBi showed unspecific cytotoxic effect on cell proliferation; Scale bars, 40µm; 
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Loss of GFP may be explained by cells being forced to become terminally differentiated O4-
expressing oligodendrocytes (hence PDGFRα-negative). We ruled out this possibility, as no 
GFP cells were activated at early stages in the screen, and the morphology of the inhibitor-
treated cells did not indicate oligodendrocytes. Alternative possibilities to explain lack of 
GFP induction would be that either cells are ‘stalled’ in an immature NS cell state (albeit no-
proliferative), or that they are forced to differentiate along alternative lineages, either 
astrocyte and/or neuronal (Figure 23).  Time-lapse movies of the differentiating cells 
suggested neuronal differentiation was unlikely, and that astrocyte differentiation may be 
occurring. Therefore we stained the inhibitor treated differentiating cultures with neuronal 
and astrocyte markers (TuJ1, GFAP). Alongside experiments in the differentiation setting we 
investigated the role of the small molecules in the proliferating setting with EGF present in 
the media to understand whether the effect we observed was 1) related to the culture 
conditions or 2) independent of the growth factors used.   
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We found that inhibitor-treated cells did not differentiate into astrocytes or neurons, as shown 
by expression levels of GFAP (astrocytic marker) lower than in DMSO-controls and BMP-4-
treated cells (positive control). Expression of TUBB3 (detected by TuJ1 immunostaining), a 
neuronal marker, was not observed (Figure 24A and B). Two different concentrations of 
DMSO were used in these experiments. DMSO control called “DMSO 2” corresponds to the 
1uM concentration of NFkBi, which has 10 times the concentration of DMSO used in the 
chemical screening. These data suggested that inhibitors were not blocking OPC induction by 
diverting cells to an alternative lineage.  Also, these compounds did not trigger differentiation 
when added to proliferating NS cells in the presence of EGF and FGF-2 (proliferation 
conditions) (Figure 24C). 
Figure 23. A schematic showing possible fate of drug-treated NS cells. GFP inhibitors block activation of 
oligodendrocyte differentiation program. These cells could self-renew as NS cells, become senescent or 
differentiate into other neural cell types: neurons or astrocytes; 
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Figure 24. Drug treatments do not lead to neural differentiation.(A,B) Immunofluorescence and qPCR analysis 
do not show increase in astrocytic (GFAP) or neuronal (TUBB3) markers during drug treatments when 
compared to GFAP (astrocytic marker) or TUBB3 (neuronal marker); Scale bars, 60µm; (C) Drug treatments do 
not lead to astrocytic differentiation in proliferating conditions (+EGF, +FGF-2); 
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An explanation for the inhibitor block could be that cells are arrested in a senescent NS cell 
state.  To explore this further I next analysed expression of p21 and p53 in both proliferating 
and differentiating drug-treated cells (Figure 25A and B). I observed upregulation of p21 and 
p53 with all drug-treatments, irrespective of growth factors used. This data suggests cells 
trigger stress response pathways in response to inhibitors and that this may interfere with 
OPC lineage commitment. I did not observe any change in the expression of Olig2, BLBP 
and Nestin, compared to normal differentiating controls, suggesting that cells can begin to 
exit the NS cell state, but fail to upregulate lineage programs (Figure 25C&D). 
Increased  levels of p21 led me to investigate whether there was an accompanying increase in 
beta-galactosidase levels, a marker often used to indicate senescence (most often in fibroblast 
cultures). Cells were differentiated for a period of five days to allow enough time for the 
cellular response and activation of intracellular pathways. Although I observed that the 
NFkBi in particular triggered increased frequency of beta-gal cells, suggesting it promotes 
cell senescence in a subset of cells, the other compounds showed only modest or no increases 
in beta-gal (Figure 25E). Cell viability showed that cells are able to recover from the drug 
treatment  and were able to start doubling again when re-exposed to self-renewal conditions 
(EGF and FGF), indicating that a significant proportion of the cells were not permanently 
arrested/senescent (Figure 25F). Altogether these data indicate that the effects of identified 
inhibitors in blocking OPC induction occur via an arrest of differentiating cells at early stages 
of differentiation and upregulation of p21, which effectively blocks differentiation to 
neuronal or glial fates. Immunofluorescence analysis showed that HDACi can effectively 
reduce the number of proliferating cells, observed as a reduction in Ki67, even in the 
presence of a potent mitogen like EGF (Figure 25G).  
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Figure 25. Drug treatments cause cellular stress. (A,B) Levels of p21 were increased in all drug treatments, in 
both proliferating and differentiating conditions; p53 expression was increase in differentiating conditions, but 
not in proliferation; (C,D) Levels of NS cell markers remain stable in proliferating and differentiating conditions; 
(E) NFkBi causes significant cell  senescence as indicated by beta-gal levels (p<0.05; double-sided t-test); (F) 
Drug treated cells can recover and continue proliferating when EGF is reintroduced in the media, however the 
increase in cell proliferation was not significant for both NFkBi and the DMSO control (double-sided t-test); (G) 
HDACi (Apicidin, HDACi III) can reduce the number of proliferating NS cells despite the presence of EGF as 
indicated by the reduction in Ki67 expression; Scale bars, 75µm; 
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5.2.4 Validation of NFkBi and its potential to trigger cell senescence 
It is not uncommon in the field of chemical screening to identify compounds, which show 
their activity through a non-specific ‘off target’ effect. This is an often inherent feature of the 
shared features of enzymatic domains (e.g. kinases). Limited knowledge about the given 
compound and its action through pathways may therefore undermine efforts to validate the 
molecular target and pathway of newly identified candidates from HCS. 
The NFkB inhibitor (NFkBi, also known as 545380-34-5, PubChem ID 509554) identified 
from the InhibitorSelect chemical screen may have promoted cellular senescence, based on 
the dramatic increase in beta gal staining. NFkB signalling is important in a range of human 
diseases, and therefore over the years many NFKB inhibitors have been developed, including 
some which have been explored in the clinic.  
We therefore compared responses of the identified NFkBi with a frequently used inhibitor of 
NFkB pathway; a molecule known as BMS-345541 (BMS). To monitor NFkB signalling I 
obtained an NFkB-GFP signalling reporter, which comprises multiple repeats of the target 
sequence upstream of GFP. PG1-1 cells were transfected (using lipofection) with the NFkB-
GFP reporter and then exposed to the two inhibitors. I analysed cells, which were treated as 
an adherent cell culture, but also cells which were in suspension. This was done for two 
reasons, firstly to investigate whether NFkBi affects cell attachment and secondly to compare 
its effect on cells in suspension, which tend to clump and form neurospheres, reducing 
exposure of the drug to the more internalised cell layers.  
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I first demonstrated that the reporter construct was working appropriate by transfecting 
control cells, and indeed I observed substantial numbers of GFP expression (from the NFkB 
promoter). This GFP expression was reduced in the presence of BMS, confirming that all 
GFP signal is the result of NFkB signalling.  Importantly, however, when treated with the 
NFkBi identified in our screen, I did not see any reduction in the GFP levels, suggesting that 
NFkB is not the molecular target of the inhibitor molecule described in the InhibitorSelect 
library as NFkBi (Figure 26A&B). Therefore the specific molecular target and pathway for 
NFkBi is likely not operating through the NFkB signalling pathway to mediate the effects on 
GFP induction. The molecular target was not pursued further given the time constraints. 
Consistent with this, while the NFkBi was effective at reducing the number of proliferating 
PG1-1 cells, both in suspension and as an adherent cell layer, after 48 and 72 hours of 
treatment (Figure 26C-F), we did not observe similar effects for BMS-345541 activity. In 
summary, the NFkB signalling pathway, while active in proliferating NS cells, does not 
therefore seem to be the important molecular pathways targeted by the NFkBi. 
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Figure 26. Validation of NFkBi potential and molecular target. (A,B) Cells with overexpressed NFkB were 
treated with Apicidin (negative control), Withaferin and BMS-345541 (positive controls) and NFkBi identified 
in the chemical screening; Reduction in NFkB levels was not observed in the NFkBi-treated cells; (C,D,E,F) 
NFkBi significantly reduces the number of proliferating cells after 48 and 72 hours of treatment (p<0.05; 
double-sided t-test); The process is not affected by culture conditions (attached cells vs cells in suspension); The 
response of BMS-345541 and NFkBi show no correlation; 
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5.2.5   Effects of inhibitors on human neural stem (NS) cells and glioblastoma-derived 
NS cells (GNS) 
The experimental goal of this project was to identify compounds, which could be used in the 
treatment of GBM. The selected compounds did not show potential to be used in a 
differentiation therapy, but they had a cytostatic effect on mouse cells and in case of NFkBi 
appeared to trigger cell senescence. Thus, we decided to investigate the effect of these small 
molecules on human GNS in hope that the GNS lines would be more sensitive to the 
treatment than control human NS cells.  We focused on two lines, called G7 and G144, which 
were derived from primary human glioblastomas. 
When NFkBi was used to treat GNS cell lines I observed a similar trend as in the mouse NS 
cell line. In particular, G7 cell line appeared to be more responsive to the NFkBi treatment in 
the presence of EGF and FGF-2 (Figure 27A-D).  The activity was dependent on the presence 
of the growth factors as none of the lines tested were responsive to the treatment in their 
absence. I did not observe an increased efficacy with 1uM concentration of NFkBi, which 
could validate 100nM concentration as a minimum effective dose of this drug. This however 
requires additional validation.  
Phase images of live cells show that cells did not change the morphology and there was no 
sign of rounded apoptotic cells. However, I observed a reduction in proliferation of the 
control human foetal cell line, named CB660 (Figure 27E&F).  
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Figure 27. NFkBi reduces proliferation of GBM cell lines. (A,B) In the absence of growth factors, GBM cells 
show decreased level of proliferation; (C,D) NFkBi at 100nM can reduce the number of proliferating GBM cells 
(G7 and G144), while NFkBi 1uM affects proliferation of the control human foetal cell line (CB660) (p<0.05, 
double-sided t-test); (E) NFkBi does not lead to cell death as shown in the microphotographs of live cells; Scale 
bars, 40µm; 
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I made a similar observation at a later time point (day 7) (Figure 28A-D). CB660 cell line 
was not proliferative, so I decided to use another foetal line, named U5, which showed that 
NFkBi at 100nM is able to inhibit the proliferation of G7 GNS cell line without cell death in 
the U5 line. The concentration of 1uM caused inhibition of foetal lines (Figure 28E and F).  
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Figure 28. 100Nm NFkBi reduces proliferation of GBM, but not control cell lines in culture. (A,B) On day 7 of 
differentiation GBM and control lines showed reduced proliferation in the absence of growth factors; (C,D) G7 
and G144 GBM cell lines showed reduced proliferation on day 7 of the drug treatment with NFkBi; (E,F) 
Control human foetal cell line (U5) is not affected by the 100nM NFkBi treatment, however it shows a reduced 
proliferation at the higher NFkBi concentration (p<0.05; two-sided t-test performed);  
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Interestingly, when other identified inhibitors identified from the screen were tested on 
human cell lines I observed that two molecules, Apicidin and Nigericin are effective 
inhibitors of proliferation. Unfortunately, however, they also inhibited proliferation of CB660 
cells with similar potency, suggesting they might not have any specific value in targetting 
glioma stem cells (Figure 29A and B).  
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Figure 29. Effect of GFP inhibitors from the StemSelect library on the proliferation of human foetal and GBM 
cell lines. Apicidin and Nigericin reduce the number of proliferating GBM cells (B; G7), but they also affect 
proliferation of the control human foetal cell line (A; CB660); Scale bars, 80µm; 
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5.3 Discussion 
Validation of inhibitors identified in the chemical screening shows the importance of a clear 
objective of the work, as molecules perform differently depending on cell lines used (mouse 
vs human), growth factors and readout measurements, e.g. Ki67 levels or confluency 
measurements.  
I observed that HDACi can selectively reduce the percentage of GFP-positive cells, though 
not completely. As my experiments show, the PDGFRα activation does not indicate 
commitment to oligodendrocyte lineage. Thus, HDACi could reverse the PDGFRα status of 
cells and turn them back into NS cells. HDACs are important for oligodendrocyte lineage 
progression. A deletion of both HDAC1 and HDAC2 results in stabilisation and nuclear 
translocation of beta-catenin, which represses Olig2 expression and oligodendrocyte lineage 
progression (Ye, Chen et al. 2009). Unspecific cytotoxicity of NFkBi is further discussed in 
General Discussion.  
Identified molecules did not lead to progression of any of the neural lineages. Instead they 
caused cell stress, as increase in level of p21 was observed.  Apicidin was shown to activate 
p21 in human prostate carcinoma cells. It causes accumulation of acetylated histones H3 and 
H4 which leads to p21 transcription (Kim, Lee et al. 2001).  In a similar setting of prostate 
cancer cells also Withaferin was shown to upregulate p21 and cause G2/M cell cycle arrest 
(Roy, Suman et al. 2013).  
Activity of NFkBi identified from the InhibitorSelect library does not correspond with the 
one of BMS-345541 (BMS), a well established, highly selective inhibitor of IKK. By 
blocking the IKK, BMS leads to reduction in NFkB activity (Burke, Pattoli et al. 2003). This 
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suggests a different molecular target for the compound identified and described as NFkB 
inhibitor in the chemical library. As literature describing this molecule is sparse other 
comparative methods of validation could be used to identify the molecular target of the drug. 
NFkBi is the most promising compound identified in the chemical screening as it showed 
specificity against human GBM cells, even though initial experiments using mouse NS cells 
did not show reduction in Ki67 expression.  
Effect of HDACi was consistent in both mouse and human cell lines, as cells exited cell 
cycle. However, a reduction in proliferation of control human cell line was observed. This 
could be still beneficial in a GBM treatment as no apoptosis in control lines was observed. 
Two HDACi, vorinostat and depsipeptide, were approved for the treatment of refractory 
cutaneous T cell lymphoma. Another HDACi, valproic acid, was tested in GBM treatment 
along with temozolomide and radiation therapy (Shabason, Tofilon et al. 2011). Another 
study showed that a combination of bortezomib, a proteasome inhibitor, with HDACi has a 
synergistic cell killing effect on primary and conventional GBM cell lines (Asklund, 
Kvarnbrink et al. 2012). This could modify the way a chemical screening is performed, 
looking for a combination of an established treatment molecule, e.g. temozolomide, with 
chemical libraries of compounds in search of a synergistic effect and a better patient 
outcome. 
5.4 Summary 
Validation of the compounds identified in the chemical screenings was performed. Apicidin 
and HDACi III selectively target GFP-positive cells and reduce their proportion in culture. 
None of the compounds leads to neural differentiation programs, causing cell stress as shown 
by upregulated levels of p21 in proliferating and differentiating conditions and p53 in 
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proliferating conditions. Drug treatments do not affect levels of NS cell markers including 
BLBP, Olig2 and Nestin. NFkBi causes cell senescence as indicated by beta-Gal levels. 
HDACi reduce the number of proliferating NS cells as indicated by reduced number of Ki67-
positive cells. A comparative analysis of NFkBi and BMS-345541, a well-established NFkBi 
inhibitor, showed no correlation in activity, suggesting a different mode of action for the 
compound described as ‘NFkBi’ in the InhibitorSelect library. 100nM NFkBi was effective at 
reducing the number of proliferating NS and GNS cell lines with a minimal effect on control 
human NS cell lines (U5, CB660). Apicidin and Nigericin can inhibit proliferation of GNS 
cells, but they also reduce proliferation of the control line.  
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Chapter 6 General Discussion  
6.1 Mouse NS cell lines as a tool to model oligodendrocyte differentiation 
Studies of developmental biology provide us with a wealth of information, allowing us to 
identify, describe and understand the function of the key genetic controls that underpin the 
formation of the central nervous system. However, in vitro studies provide a powerful 
complementary experimental platform that is well suited to defining cell intrinsic 
mechanisms of lineage choice and differentiation, and enable simplified biochemical analysis 
of underlying mechanisms. Knowledge of how to manipulate stem and progenitor cells in 
vitro will also be essential for cell based human disease modelling, and cell based therapies. 
This knowledge is also highly applicable to studies of human cancer. 
Protocols have been developed to generate oligodendrocyte progenitors from multipotent 
neural stem cells, through oligodendrocyte progenitor cells and immature oligodendrocytes to 
fully functional oligodendrocytes expressing myelin basic protein. However, these protocols 
are highly variable in efficiency and typically unreliable. Here I have demonstrated that  
a differentiation protocol using PDGF and FGF-2 allows for a development of ~15% 
PDGFRα-positive OPCs. In a study using retroviruses to drive PDGF expression Assanah et 
al. observed that less than 20% of cells in a formed tumour mass express the GFP reporter, 
which corresponds with my findings of PDGFRα activation when NS cells are cultured in 
vitro in the presence of PDGF (Assanah, Lochhead et al. 2006). Therefore, both in vitro and 
in the context of cancer models, OPC specification seems to be restricted. In search of 
molecular pathways involved in OPC specification I have generated and validated in a useful 
PDGFRα-GFP reporter cell line and carried out chemical screening. 
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My results suggest that cell plating density is one of the most important factors affecting 
progression of NS cells into OPCs, and that this can be influenced by both autocrine and 
paracrine signalling. I observed a direct positive correlation between number of cells plated 
and percentage of OPCs in culture, higher plating density meaning higher percentage of 
OPCs in culture. My observation expands on the findings of Yang et al. where they showed 
the importance of density for maturation of oligodendrocytes as I show its relevance for the 
initial step of lineage progression, the activation of PDGFRα. Similarly to my findings, 
Nakatsuji and Miller also observed that the state of an OPC is reversible. Despite cell cycle 
exit and activation of p27(Kip1) when replated OPCs, I observed that cells can re-enter the 
cell cycle and revert to an NS cell state. In future studies it would be of interest to determine 
whether commitment to differentiation occurs at the later time point when O4 is activated and 
PDGFRα expression extinguished. O4-positive cells could be sorted using FACS and plated 
at different densities, in a presence of EGF. This could allow to answer a number of 
questions: 1) Do O4-positive cells respond to the plating density and EGF in a way similar to 
PDGFRα-positive OPCs? 2) Does the plating density affect the differentiation potential of 
O4-positive cells? 3) Do O4-positive cells divide in the presence of EGF? 4) Is the O4-
positive state reversible, or does it represent a point of lineage commitment? 
If results were promising, this would stimulate interest in using the O4 marker as an endpoint 
in chemical screening to identify molecules driving this process or by modifying the 
differentiation protocol, something which I have only explored briefly in this project. Use of 
FACS allows for selection of distinct cell populations.  
The commitment to the oligodendrocyte lineage is particularly important from the 
perspective of the GBM differentiation therapy, where tumour cells could be potentially 
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locked into this more differentiated and less aggressive state. Cells would then become 
irresponsive to mitogenic growth factors like EGF. Thus, both progression of NS cells into 
OPCs and their commitment to the lineage are important to the success of the differentiation 
therapy. Indeed spontaneous differentiation into oligodendrocytes is a feature of subtypes of 
GBM – although it remains unclear whether these are truly postmitotic. 
The plating density effect on the efficiency of OPC specification is likely to be related to the 
Notch signalling pathway. A neurosphere study by Grandbarbe et al. showed that a lack of 
Notch signalling decreased a number of PDGFRα-positive cells, leading to MAP2-positive 
neuronal cells (Grandbarbe, Bouissac et al. 2003). The Notch pathway defines cell fate 
decisions by interactions between cellular neighbours. A validation of Notch signalling in my 
in vitro system could be performed by firstly analysing the expression levels of Notch and its 
ligand proteins Jagged and Delta in both proliferating and differentiating conditions, followed 
by a similar analysis in the presence of a Notch inhibitor molecule.  
Interestingly, the compound identified in the screening for O4 cells called a gamma-Secretase 
Inhibitor IX inhibits Notch signalling and promotes differentiation of OPCs, most likely at 
the cost of other GFP-negative cells. Further focus on the gamma-Secretase Inhibitor IX is 
clearly an area of interest in future studies.   
6.2 Chemical screening – technical considerations 
The chemical screening performed in this thesis was carried out as four independent 
experiments, performed over a 6-month span. Therefore, the identified molecules, 
particularly the multiple HDAC inhibitors that were identified, represent a clear and 
significant finding from my thesis. HDAC inhibitors clearly affect the ability of the 
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oligodendrocyte specification program to emerge. Although we did not identify chemicals 
that could stimulate increased OPC production, the progress that we have made in 
establishing the reporter cell lines and optimisation of the screening protocols and analysis 
pipeline now means that we could extend the assay to other libraries of compounds. 
The HCS method described here allows for a screening of hundreds, or even thousands of 
compounds with a wide variety of functions ranging from inducers, activators and agonists to 
antagonists of cellular pathways and other modulators of cell fate, which can be used in 
studies of cellular survival, proliferation, migration, invasion, differentiation and fate 
determination. Potential improvement and future directions for the screening strategy could 
include adaptation to the 384-well plate system, which would make the whole process more 
time-efficient, as the time handling cells, plates and chemical libraries could be significantly 
reduced. Moreover, the 384-well plates require less volume, which in turn reduces the 
volumes of drugs used. Another practical advantage would be freeing of space in the imaging 
device, as one 384-well plate would replace four 96-well plates. This would offer an 
opportunity to perform more technical replicates of experiments at the same time.  
For my studies I used a mouse NS reporter cell line expressing GFP from the endogenous 
locus of PDGFRα, which marks oligodendrocyte lineage progression. This system using 
adherent NS cell lines could be further developed as new lines e.g. MBP-GFP would offer a 
valuable insight into processes driving oligodendrocyte lineage progression. Moreover, we 
could investigate other neural lineages, establishing reporter lines for neuronal and astrocytic 
differentiation using markers like Tuj1 or GFAP. A powerful future step would be to include 
multiple reporters using distinct fluorescent proteins within the same cell line, enabling 
multiplex monitoring of fate choice. 
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In the chemical screening I identified a number of false-positive molecules, acting as both 
inhibitors and inducers of GFP activation. These molecules, when tested using flow 
cytometry, did not show the expected results. A common problem was compound 
autofluorescence and its accumulation inside of cells. In the validation step of the five 
selected small molecules I observed a differential response to drug treatment when replicates 
of experiments were performed. Small molecules in some instances showed a lack of effect 
on GFP expression or a cytotoxic effect. This could be due to decreased drug stability in 
solution, which is crucial for a success of any chemical screening-based study. 
The chemical stability of compounds in chemical libraries can be affected by environmental 
conditions during a long-term storage. Other factors, which can affect compound stability 
include compound concentration, presence of reactive contaminants, intrinsic compound 
stability, storage-related factors: container, sealing, storage time, temperature, humidity and 
freeze-thaw cycles (Blaxill, Holland-Crimmin et al. 2009). Most compounds in chemical 
libraries are dissolved in DMSO, which is hygroscopic and quickly absorbs water from the 
atmosphere. Water can accelerate degradation and precipitation of compounds, if present in 
DMSO compound solutions. Exposure of the library to the laboratory environment and its 
humidity levels were shown to play role in this process (Ellson, Stearns et al. 2005).  
Small molecules analysed in this thesis were diluted from the original stock concentration in 
order to achieve the final screening concentration of 1uM. As 1% DMSO was cytotoxic to 
cells, the final drug dilution was obtained by using phosphate buffered saline (PBS) instead 
of DMSO to reduce the final DMSO concentration. PBS is a water-based salt solution, which 
could explain the reduced activity of small molecules in some experimental replicates.  
A good practice would be to separately purchase compounds selected for further investigation 
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and store them in small aliquots, which could be used and discarded after a single experiment 
without a need for a freeze/thaw cycle. Moreover, this would reduce the need to use the 
chemical library stock, limiting its exposure to harmful factors and promoting drug stability, 
which can improve consistency of outcomes in experimental replicates.  
6.3 Chemical screening – findings 
The aim of this work was to isolate compounds modulating lineage choice of neural stem 
cells and thus to dissect pathways responsible for the process of neural differentiation. This 
knowledge could be then used in the field of GBM research, leading cancer stem cells to a 
post-mitotic differentiated state. Moreover, efficient differentiation of NS cells in vitro could 
allow for their use in regenerative medicine applications. Five molecules identified in the 
chemical screening were validated for their ability to block GFP expression and further 
characterised.  
The observation of HDACi as the most prominent family of compounds is of importance. It is 
necessary to consider that these molecules inhibit HDACs, which reversibly modify core 
histones terminals, a process considered to be a major epigenetic mechanism used to 
regulated gene expression in cells. The process can affect histones, but also other non-histone 
proteins like transcription factors, which function can be modified by acetylation. HDAC1 is 
involved in a regulation of the Notch signalling pathway together with another co-repressor 
called SMART. The SMART/HDAC1 complex can turn off transcription of Notch target 
genes (Kao, Ordentlich et al. 1998). HES5, which is a downstream target of Notch signalling, 
inhibits expression of Sox10 and MBP (Liu, Li et al. 2006).  
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HDACs can also affect the Wnt pathway, which is involved in inhibition of the 
oligodendrocyte differentiation (Shimizu, Kagawa et al. 2005). This is possible due to their 
recruitment by Groucho-related proteins GRO, TLE and GRG (Sekiya and Zaret 2007). In 
this relation, HDACs could act together with Groucho-related proteins to inhibit Wnt and in 
turn activate the oligodendrocyte differentiation process.  
Interestingly, Foti et al. used VPA, one of the HDACi identified in the StemSelect screening, 
to show that neural stem cells switch expression of HDAC1 and HDAC2 as they commit to a 
neurogenic lineage in the SVZ and DG. VPA reduced the number and differentiation of cells 
in the DG, RMS and OB (Foti, Chou et al. 2013). Ye at al. reported that a deletion of both 
HDAC1 and HDAC2 results in the stabilisation and nuclear translocation of beta-catenin, 
which represses Olig2 expression and oligodendrocyte lineage progression. Double knockout 
animals died around P14. Markers of the oligodendrocyte lineage, Olig2 and PDGFRα were 
lost at E15.5, with no markers of mature oligodendrocytes at P4. Moreover, when primary 
cells from double-null mice were cultured in vitro they did not differentiate into 
oligodendrocytes (Ye, Chen et al. 2009).  
Shen et al. showed that histone deacetylation is essential for the correct timing of 
oligodendrocyte differentiation during development in vivo. Inhibition of histone deacetylase 
activity during the first 10 postnatal days resulted in hypomyelination and delayed expression 
of differentiation markers. VPA administration after myelination onset did not affect the 
myelin gene expression (Shen, Li et al. 2005). In a later study, Shen et al. found that an 
increased activity of histone deacetylases correlates with the ability to remyelinate 
demyelinated lesions in young animals (Shen, Sandoval et al. 2008).  
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Our finding therefore builds on the literature that HDACs play a critical role in the 
oligodendrocyte specification. Our future studies should therefore focus mechanistically on 
how HDACi affect the Olig2 and the links between Olig2 and PDGFRα transcriptional 
activation. The cell lines we have developed and characterised clearly provide a convenient 
model to explore the specific mechanistic basis further. 
Apicidin was shown to inhibit class II HDAC4 in a study of human ovarian cancer cell 
migration (Ahn, Kang et al. 2012), while another study showed its specificity for HDAC2 
and HDAC3, both class I molecules (Khan, Jeffers et al. 2008). HDACi III, also known as 
m344, causes increase in hyperacetylated histone H4 and shows selectivity for HDAC6, a 
class IIB HDAC. It is worth mentioning that HDACs 2 and 3 are localised in the nucleus, 
while HDAC6 is mostly in the cytoplasm and shuttles in and out of the nucleus depending on 
the signalling. The fact that the two HDACi block different histone deacetylases suggests that 
the effect on oligodendrocyte differentiation is unspecific and related more to the overall cell 
cycle exit and gene regulation action of HDACs than a specific cellular mechanism.  
My observation is that HDACi are important not only for the timing of oligodendrocyte 
differentiation or their myelination potential, but also for the initial lineage specification from 
a neural stem cell/radial glia progenitor to a PDGFRα-expressing OPC. Chemical screening 
focused on families of HDAC inhibitors could prove to be very beneficial to expand on this 
and previously reported studies. We could also explore further how the role of different 
HDACs changes over time, in proliferation and after induction of differentiation. This way 
we could also control cell populations, regulating their lineage progression by treatment using 
specific HDACs. Ultimately the genetic loss of function will be required to define whether 
there are specific HDAC family members that are required for the NS cell to OPC transition.  
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Nigericin is able to completely block expression of PDGFRα. However, this effect could be 
due to cytotoxicity, as Salinomycin, a closely related ionophore was shown to be cytotoxic 
against the neural cells. This effect is due to elevated cytosolic concentration of sodium ions, 
which in turn cause increase in cytosolic calcium ions, because of the sodium/calcium 
exchangers’ activity (NCXs). Elevated levels of Ca2+ lead to calpain activation and caspase-
dependent apoptosis (Boehmerle and Endres 2011). This could explain why cells did not 
differentiate into OPCs, but instead retained the morphology of the NS cells, or were 
apoptotic in case of PDGFRα-positive cells treated with Nigericin.  
Withaferin A has been reported to inhibit the NFkB activity. Described as a steroidal lactone, 
Withaferin can also bind to and inhibit Vimentin, causing the filaments to aggregate in vitro. 
It has a potent dominant-negative effect on F-actin, which requires Vimentin expression and 
induces apoptosis (Bargagna-Mohan, Hamza et al. 2007). Withaferin acts as a potent 
inhibitor of angiogenesis through a process associated with inhibition of cyclin D1 expression 
(Mohan, Hammers et al. 2004). Withaferin downregulates expression of GFAP by covalently 
binding it at cysteine 294 and causes G0/G1 cell cycle arrest (Bargagna-Mohan, Paranthan et 
al. 2010). It is then possible that the lack of PDGFRα activation is due to the cell cycle arrest 
at an early stage of NS cell, which does not allow for a progression to an OPC.  
6.4 Validation of NFkBi 
NFkBi was the most promising candidate compound identified in the chemical screening as 
we found that it could reduce proliferation of GBM cell lines in the presence of EGF and 
FGF. However, we failed to recapitulate the same response with the widely used and potent 
NFkB inhibitor BMS-345541, suggesting the NFkBi is operating through some other 
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pathway or target. Furthermore PG1 cells that were lipofected with an NFkB GFP reporter 
plasmid indicated no reduction in GFP expression in NFkBi treated cells.  
The NFkBi compound was created using structure-activity relationship (SAR) studies. It is 
based on quinazoline derivative 6a, which elucidates requirements for NFkB inhibition 
(Tobe, Isobe et al. 2003). In a study by Tobe et al this compound is described as 11q. It 
contains a 4-phenoxyphenethyl moiety at the C(4)-position and showed strong inhibitory 
effects on both NFkB transcriptional activation and TNFα production in the original study 
using Jurkat cells. The target protein for the activity of NFkBi was not identified in that 
study, thus it was not immediately possible to answer whether the difference between NFkBi 
and BMS-345541 can be explained by a different molecular target. 
Some of the drugs approved for patient treatments have no known primary molecular target 
and lack a well-defined mechanism of action.  Bioinformatics tools are used to address this 
problem. Based on chemical similarities between drugs and structurally known ligands it is 
possible to predict their interactions (Keiser, Setola et al. 2009). A similar approach could 
help to identify the molecular target of the NFkBi. Alternatively, affinity methods could be 
used. NFkBi would be then tethered to a solid support and exposed to a cell extract. Small 
molecule-protein binding interaction could be observed and the target confirmed. These 
directions are a major undertaking and beyond the scope of this thesis. 
6.5 Chemical screening as a tool for differentiation therapy  
Our knowledge gained from the differentiation studies in vitro could be useful in the field of 
GBM research, leading cancer stem cells to a post-mitotic differentiated state. Moreover, 
efficient differentiation of NS cells in vitro could allow for their use in regenerative medicine 
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applications. With the use of differentiation therapy cancer stem cells could lose their stem 
cell properties, making them more susceptible to cytotoxic treatment and preventing their 
growth. 
Mouse NS cells are easier to work with than human NS and GNS cells, as they proliferate 
more rapidly and are easily genetically manipulated. This is the reason why in this study I 
focussed on mouse NS cells and only then moved to test molecules for their effects on human 
GNS cells. Unfortunately, we failed to uncover small molecules that potently drove the 
process of differentiation – either to oligodendrocyte or neuronal and astrocyte lineages. 
However, future chemical screening could be performed directly on GNS lines. With the 
advent of improved technologies for genome editing directly in human NS and GNS cells it 
has become feasible to engineer live cell GFP reporters, and this will open up new 
opportunities for HCS of human stem cells. 
In conclusion, I have developed tools and assays that enable live cell screening for 
modulation of neural stem cell fate. Screening of further chemical libraries may provide new 
insights into molecular mechanisms underlying NS cell differentiation and reveal small 
molecules that can be used as chemical ‘tools’ to study basic mechanisms. Although 
unsuccessful in our attempts to identify agents that can efficiently promote differentiation, the 
search for such compounds is important and may lead to new types of differentiation therapy 
for brain tumours. 
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